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ABBREVIATIONS 
 
ACTH  -  Adrenocorticotropic hormone 
ADCME -  Autosomal dominant cortical myoclonus and epilepsy 
ADNFLE -  Autosomal dominant nocturnal frontal lobe epilepsy 
AED  -  Anti-epileptic drug 
ASE  -  Absence status epileptics 
BID  -  Giving medication twice per day 
CAE  -  Childhood absence epilepsy 
CNS  -  Central nervous system 
CSF  -  Cerebrospinal fluid 
CT  -  Computed tomography 
DDI  -  Drug–drug interaction 
ECG  -  Electrocardiography/electrocardiogram 
EEG  -  Electroencephalography/electroencephalogram 
FS  -  Febrile seizures 
 
GABA  -  Gamma-amino butyric acid 
 
IGE  -  Idiopathic generalised epilepsy 
 
LFTLE -  Lateral familial temporal lobe epilepsy 
 
MFTLE -  Mesial familial temporal lobe epilepsy 
 
MRI  -  Magnetic resonance imaging epilepsy 
 
SUDEP -  sudden unexpected death in epilepsy 
 
TLE  -  Temporal lobe epilepsy 
 
VNS   -  Vagal nerve  stimulation 
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INTRODUCTION 
 
While the Evaluation and treatment of patient with seizures (or) epilepsy, is 
often challenging. Modern therapy[1] provides many patient with seizure control. After 
a first seizure evaluation should focus on excluding an underling neurologic or 
medical condition assessing the relative risk of seizure reoccurrence & determining 
whether treatment is indicated. Successful management of patient with recurrent 
seizure[2] begins with the establishment of accurate diagnosis of epilepsy syndrome  
followed by treatment using an appropriate medication in a manner to optimize the 
efficacy. The goal of AED’s therapy is to completely control seizures with producing 
Un acceptable medication [4] side effects. 
 
Patients who do not achieve complete seizure control should refer to an 
epilepsy specialist. Since new medication and surgical treatment offers patients 
unprecedented options in seizure control.[9] 
 
          Newly diagnosed epileptic patients and principles of treatment in chronic 
epilepsy help in designing steps to improve the safety of drug use in the hospital 
working setup. Better health care practice could be ensured by applying this 
knowledge to individual patients.[18] 
 
     Present study was undertaken to understand the treatment outcome of AED’s 
observed in neurology unit of a teaching hospital with regarding to demographics of 
patients, choice of prescribed AED’s usual dosing regimens and faster routine 
incremental and decrimental rates, management of seizures & identify precipitating 
factors [21] of epilepsy.  
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2. SUBJECTIVE INTRODUCTION 
 
2.1 DEFINITION 
Epilepsy is the tendency to have seizures that start in the brain. The brain uses 
electrical signals to pass messages between brain cells. If these signals are disrupted, 
this can lead to a seizure. 
 
Epilepsy is usually diagnosed when someone has more than one seizure. 
Seizures can vary a lot. They can affect your feelings, awareness or movement. 
Different types of seizures involve different things. These may include confusion, 
strange feelings, repetitive movements, 'blank' moments  muscle jerks, sudden falls, or 
convulsions.  
 
Seizures are caused by disturbances in the electrical activity of the brain. 
 65 MILLION: Number of people around the world who have epilepsy. 
 NEARLY 3 MILLION: Number of people in the United States who have 
epilepsy. 
 1 IN 26 people in the United States will develop epilepsy at some point in their 
lifetime. 
 BETWEEN 4 AND 10 OUT OF 1,000: Number of people on earth who live 
with active seizures at any one time. 
 150,000: Number of new cases of epilepsy diagnosed in the United States each 
year 
 ONE-THIRD: Number of people with epilepsy who live with uncontrollable 
seizures because no available treatment works for them. 
 6 OUT OF 10: Number of people with epilepsy where the cause is unknown. 
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Epilepsy is thought to be one of the oldest medical conditions and may be as old 
as humankind itself. Some of the earliest medical texts describe events that likely 
were seizures. Jackson defined a seizure as "an occasional, an excessive, and a 
disorderly discharge of nerve tissue on muscles." 
 
Epilepsy is a group of neurological diseases characterized by epileptic seizures. 
Epileptic seizures are episodes that can vary from brief and nearly undetectable to 
long periods of vigorous shaking. In epilepsy, seizures tend to recur, and have no 
immediate underlying cause [35] while seizures that occur due to a specific cause are 
not deemed to represent epilepsy.[37] 
 
The cause of most cases of epilepsy is unknown, although some people 
develop epilepsy as the result of brain injury, stroke, brain tumors, and substance use 
disorders. Known genetic mutations are directly linked to only a small proportion of 
cases.[38] Epileptic seizures are the result of excessive and abnormal cortical nerve cell 
activity in the brain. The diagnosis typically involves ruling out other conditions that 
might cause similar symptoms such as fainting. Additionally, making the diagnosis 
involves determining if any other cause of seizures is present such as alcohol 
withdrawal or electrolyte problems. This may be done by imaging the brain and 
performing blood tests. Epilepsy can often be confirmed with an 
electroencephalogram (EEG), but a normal test does not rule out the condition. 
 
Seizures are controllable with medication in about 70% of cases.[39] In those 
whose seizures do not respond to medication, then surgery, neurostimulation, or 
dietary changes may be considered. Not all cases of epilepsy are lifelong, and some 
people improve to the point that treatment is no longer needed. 
 
About 1% of people worldwide (65 million) have epilepsy, and nearly 80% of 
cases occur in developing countries. In 2013 it resulted in 116,000 deaths up from 
112,000 deaths in 1990. Epilepsy becomes more common as people age.[43] In the 
developed world, onset of new cases occurs most frequently in infants and the elderly; 
in the developing world this is in older children and young adults, due to differences 
in the frequency of the underlying causes. About 5–10% of all people will have an 
unprovoked seizure by the age of 80, and the chance of experiencing a second seizure 
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is between 40 and 50%. In many areas of the world those with epilepsy either have 
restrictions placed on their ability to drive or are not permitted to drive, butmost are 
able to return to driving after a period of time without seizures.  
 
Seizure 
A seizure is a short episode of symptoms caused by a burst of abnormal 
electrical activity in the brain. Typically, a seizure lasts from a few seconds to a few 
minutes. (Older words for seizures include convulsions and fits.) 
 
The brain contains millions of nerve cells (neurons). Normally, the nerve cells 
are constantly sending tiny electrical messages down nerves to all parts of the body. 
Different parts of the brain control different parts and functions of the body. 
Therefore, the symptoms that occur during a seizure depend on where the abnormal 
burst of electrical activity occurs. Symptoms that may occur during a seizure can 
affect your muscles, sensations, behaviour, emotions, consciousness or a combination 
of these. The different types of seizures are discussed below. 
 
The most common type (60%) of seizures are convulsive. Of these, one-third 
begin as generalized seizures from the start, affecting both hemispheres of the brain. 
Two-thirds begin as partial seizures (which affect one hemisphere of the brain) which 
may then progress to generalized seizures. The remaining 40% of seizures are non-
convulsive. An example of this type is the absence seizure, which presents as a 
decreased level of consciousness and usually lasts about 10 seconds 
 
Partial seizures are often preceded by certain experiences, known as auras. 
They include sensory (visual, hearing, or smell), psychic, autonomic, and motor 
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phenomena. Jerking activity may start in a specific muscle group and spread to 
surrounding muscle groups in which case it is known as a Jacksonian march. 
Automatisms may occur, which are non-consciously-generated activities and mostly 
simple repetitive movements like smacking of the lips or more complex activities 
such as attempts to pick up something. 
 
A person is considered to have epilepsy if they meet any of the following 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. At least two unprovoked (or reflex) seizures occurring greater than 24 hours apart. 
2. One unprovoked (or reflex) seizure and a probability of further seizures similar to 
the general recurrence risk (at least 60%) after two unprovoked seizures, 
occurring over the next 10 years. 
3. Diagnosis of an epilepsy syndrome 
4. Epilepsy is considered to be resolved for individuals who had an age-dependent 
epilepsy syndrome but are now past the applicable age or those who have 
remained seizure-free for the last 10 years, with no seizure medicines for the last 
5 years. 
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2.2 Different types of epilepsy and seizures 
 
 
Seizures are divided into two main types - generalised and focal (used to be called 
partial). (There are also other uncommon types of seizure.) If you have epilepsy you 
usually have recurrences of the same type of seizure. However, some people have 
different types of seizures at different times. 
 
Generalised seizures 
These occur if the abnormal electrical activity affects all or most of the brain. 
The symptoms tend to be general and involve much of your body. 
There are various types of generalised seizure: 
 A tonic-clonic seizure is the most common type of generalised seizure. With this 
type of seizure your whole body stiffens, you lose consciousness and then your 
body shakes (convulses) due to uncontrollable muscle contractions. 
 Absence seizure is another type of generalised seizure. With this type of seizure 
you have a brief loss of consciousness or awareness. There is no convulsion, you 
do not fall over and it usually lasts only seconds. Absence seizures mainly occur 
in children. 
 A myoclonic seizure is caused by a sudden contraction of the muscles, which 
causes a jerk. These can affect the whole body but often occur in just one or both 
arms. 
 A tonic seizure causes a brief loss of consciousness and you may become stiff 
and fall to the ground. 
Subjective introduction 
 
Department of Pharmacy Practice, K.M. College of Pharmacy  Page 7 
  
 An atonic seizure causes you to become limp and to collapse, often with only a 
brief loss of consciousness 
 
Focal seizures 
In focal seizures the burst of electrical activity starts in, and stays in, one part of the 
brain. Therefore, you tend to have localised (focal) symptoms. Different parts of the 
brain control different functions and so symptoms depend on which part of the brain 
is affected: 
 Simple focal seizures are one type. You may have muscular jerks or strange 
sensations in one arm or leg. You may develop an odd taste, or pins and needles 
in one part of your body. You do not lose consciousness or awareness. 
 Complex focal seizures are another type. These commonly arise from a part of 
the brain (called a temporal lobe) but may start in any part of the brain. 
Therefore, this type is sometimes called temporal lobe epilepsy. Depending on 
the part of the brain affected, you may behave strangely for a few seconds or 
minutes. For example, you may fiddle with an object, or mumble, or wander 
aimlessly. In addition, you may have odd emotions, fears, feelings, visions or 
sensations. These differ from simple focal seizures in that your consciousness is 
affected. You may not remember having a seizure. 
Sometimes a focal seizure develops into a generalised seizure. This is called a 
secondary generalised seizure. 
 
2.3 Causes of epilepsy 
 
 
Unknown cause (idiopathic epilepsy) 
In many cases, no cause for the seizures can be found. The abnormal bursts of 
electrical activity in the brain occur for no known reason. It is unclear why they start, 
or continue to occur. Hereditary (genetic) factors may play a part in some cases. 
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People with idiopathic epilepsy usually have no other brain (neurological) condition. 
Medication to control seizures usually works very well. 
 
Symptomatic epilepsy 
In some cases, an underlying brain condition or brain damage causes epilepsy. 
Some conditions are present at birth. Some conditions develop later in life. There are 
many such conditions - for example: 
 A patch of scar tissue in a part of the brain. 
 A head injury. 
 A stroke. 
 Cerebral palsy. 
 Some genetic syndromes. 
 Growths or tumours of the brain. 
 Previous infections of the brain such as meningitis and encephalitis. 
 
The condition may irritate the surrounding brain cells and trigger seizures. 
Some underlying conditions may cause no other problems apart from seizures. In 
other cases, the underlying condition may cause other problems or disabilities in 
addition to the seizures. 
These days, with modern scans and tests, a cause can be found for some cases 
previously thought to be of unknown cause. For example, a small piece of scar tissue 
in the brain or a small anomaly of some blood vessels inside the brain. These may 
now be found by modern brain scanning equipment which is more sophisticated than 
in the past. 
 
Triggers a seizure 
There is often no apparent reason why a seizure occurs at one time and not at 
another. However, some people with epilepsy find that certain triggers make a seizure 
more likely. These are not the cause of epilepsy but may trigger a seizure on some 
occasions. 
Possible triggers may include: 
 Stress or anxiety. 
 Some medicines such as antidepressants, antipsychotic medication (these lower 
the seizure threshold in the brain). 
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 Lack of sleep, or tiredness. 
 Irregular meals (or skipping meals) which may cause a low blood sugar level. 
 Heavy alcohol intake or using street drugs. 
 Flickering lights such as from strobe lighting or video games. 
 Periods (menstruation). 
 Illnesses which cause high temperature (fever) such as flu or other infections.  
 
Postictal 
After the active portion of a seizure, there is typically a period of confusion 
referred to as the postictal period before a normal level of consciousness returns. It 
usually lasts 3 to 15 minutes[43] but may last for hours. Other common symptoms 
include feeling tired, headache, difficulty in speaking, and abnormal behaviour. 
Psychosis after a seizure is relatively common, occurring in 6–10% of people. Often 
people do not remember what happened during this time. Localized weakness, known 
as Todd's paralysis, may also occur after a partial seizure. When it occurs it typically 
lasts for seconds to minutes but may rarely last for a day or two. 
 
Psychosocial 
Epilepsy can have adverse effects on social and psychological well-being. 
These effects may include social isolation, stigmatization, or disability. They may 
result in lower educational achievement and worse employment outcomes. Learning 
disabilities are common in those with the condition, and especially among children 
with epilepsy. The stigma of epilepsy can also affect the families of those with the 
disorder. 
 
Certain disorders occur more often in people with epilepsy, depending partly 
on the epilepsy syndrome present. These include depression, anxiety, obsessive–
compulsive disorder (OCD), and migraine. Attention deficit hyperactivity disorder 
affects three to five times more children with epilepsy than children in the general 
population. ADHD and epilepsy have significant consequences on a child's 
behavioral, learning, and social development. Epilepsy is also more common in 
children with autism.  
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2.4 EPIDEMIOLOGY  
EPILEPSY is a disorder characterized by recurrent seizures of cerebral origin, 
presenting with episodes of sensory, motor or autonomic phenomenon with or without 
loss of consciousness. Epilepsy is the second most common chronic neurological 
condition seen by neurologists. It is estimated that there are 55,00,000 persons with 
epilepsy in India, 20,00,000 in USA and 3,00,000 in UK. Three to five per cent of the 
population have a seizure sometime in their life and half to one per cent of the 
population have ‘active epilepsy’. 
 
Incidence, prevalence and mortality studies provide crucial measures of the 
frequency and therefore the burden of the disease and allow the planning of services. 
The applications of epidemiological techniques in the field of epilepsy have extended 
beyond the usual concept of prevalence and incidence. The objectives of 
epidemiological studies also include 
 (1) Identification of risk factors for epilepsy and to estimate the effect of potential 
interventions; 
 (2) To determine overall prognosis for seizure control and the identification of factors 
which may modify this prognosis; 
 (3)To assess the risk for other conditions in both the patient as well as in relatives  
 (4)To evaluate interventions, including drug trials. 
 
If you have epilepsy, it means that you have had repeated seizures.  
Epilepsy can affect anyone at any age. Around 456,000 people in the UK have 
epilepsy. Epileptic seizures arise from within the brain. A seizure can also be caused 
by external factors which may affect the brain. For example, a high temperature 
(fever) may cause a febrile convulsion. Other causes of seizures include lack of 
oxygen, a low blood sugar level, poisons and a lot of alcohol. Seizures caused by 
these external factors are not classed as epilepsy likely to occur, they also spread more 
readily than in a fully developed brain. The rise in the incidence of epilepsy in adults 
as they age is due to changes in the brain caused by tumors and strokes and other 
brain abnormalities. This understanding of seizures and epilepsy, the 
oldest anticonvulsant drug still in common use, was developed in 1912; the ketogenic 
diet was first put into use in 1920. From the twentieth century on there has been a 
Subjective introduction 
 
Department of Pharmacy Practice, K.M. College of Pharmacy  Page 11 
  
steady stream of new epilepsy treatments and breakthroughs in medical 
understanding. 
 
Alongside medical advances, significant progress has been made in reducing 
the social stigma and discrimination sometimes associated with epilepsy. This effort 
has been led by organizations such as the Epilepsy Foundation of America, founded in 
1968, and legislation such as the Americans with Disabilities Act of 1990. 
 
Today medical researchers are actively pursuing better treatments for epilepsy 
and ultimately a cure. At the same time, local, regional, national, and international 
epilepsy organizations are working to educate people about the disorder in an effort to 
eliminate stigma and discrimination. 
Epilepsy affects between 1 and 3 percent of the population. In the United 
States alone, approximately 180,000 new cases of epilepsy are diagnosed each year, 
and in 2004, 2.7 million Americans were living with the disorder. 
 
Epilepsy affects people of all ages, both sexes, and all ethnic groups. Children 
under the age of 2 and adults over 65 are more likely to develop epilepsy than any 
other age group. This is explained in part by changes that occur in the brains of people 
early and late in life. During childhood brain development, for example, seizures are 
not only more Approximately 300,000 American children under the age of 14 have 
epilepsy, with approximately 45,000 diagnosed each year. Males have a slightly 
higher incidence than females, and socioeconomically disadvantaged populations may 
also be at higher risk for the disorder. 
 
In approximately 70 percent of cases, no cause can be determined. Of the 
known causes of epilepsy, some of the most common are brain injury, abnormal brain 
development prior to birth, lack of oxygen during or following birth, infection of the 
brain or surrounding tissues, and abnormal structures such as tumors in the brain. 
Although genetics likely to play a role in many cases of epilepsy, in most cases it is 
impossible to determine a clear pattern of inheritance from one family member to 
another. 
 
Anticonvulsant medications are the first line of treatment for epilepsy. In 
approximately half of all cases, seizures are controlled or eliminated with a single 
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medication—often the first medication prescribed—and these success rates have 
improved as new drugs have been developed. Approximately one-third of childhood 
epilepsy cases are said to be intractable, meaning that two or more medications have 
failed to control the child's seizures. In these cases, physicians typically pursue other 
treatment options, including dietary therapies, surgery, or vagus  nerve  stimulation. 
 
Finding an effective treatment sometimes takes time. However, due to the 
variety of options available, many children with epilepsy can expect their seizures to 
be fully controlled and can look forward to living full, happy, productive lives. 
 
2.5 ETIOLOGY 
Epilepsy can have both genetic and acquired causes, with interaction of these 
factors in many cases. Established acquired causes include serious brain trauma, 
stroke, tumours and problems in the brain as a result of a previous infection. In about 
60% of cases the cause is unknown. Epilepsies caused by genetic, congenital, or 
developmental conditions are more common among younger people, while brain 
tumors and strokes are more likely in older people. Seizures may also occur as a 
consequence of other health problems; if they occur right around a specific cause, 
such as a stroke, head injury, toxic ingestion or metabolic problem, they are known as 
acute symptomatic seizures and are in the broader classification of seizure-related 
disorders rather than epilepsy itself. 
 
1. Genetics 
Genetics is believed to be involved in the majority of cases, either directly or 
indirectly. Some epilepsies are due to a single gene defect (1–2%); most are due to the 
interaction of multiple genes and environmental factors. Each of the single gene 
defects is rare, with more than 200 in all described. Most genes involved affect ion 
channels, either directly or indirectly. These include genes for ion channels 
themselves, enzymes, GABA, and G protein-coupled receptors. 
 
In identical twins, if one is affected there is a 50–60% chance that the other will 
also be affected.[38] In non-identical twins the risk is 15%.These risks are greater in 
those with generalized rather than partial seizures. If both twins are affected, most of 
the time they have the same epileptic syndrome (70–90%). Other close relatives of a 
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person with epilepsy have a risk five times that of the general population. Between 1 
and 10% of those with Down syndrome and 90% of those with Angel man syndrome 
have epilepsy.  
 
2. Acquired 
Epilepsy may occur as a result of a number of other conditions including tumors, 
strokes, head trauma, previous infections of the central nervous system, genetic 
abnormalities, and as a result of brain damage around the time of birth. Of those with 
brain tumors, almost 30% have epilepsy, making them the cause of about 4% of cases. 
The risk is greatest for tumors in the temporal lobe and those that grow slowly. Other 
mass lesions such as cerebral cavernous malformations and arterio venous 
malformations have risks as high as 40–60%. Of those who have had a stroke, 2–4% 
develop epilepsy.  
 
3. Risk Factors  
Risk factors are factors that increase the possibility of getting a condition. The risk 
factors for epilepsy are: 
 Malnutrition 
 Injury to the brain 
 Head injury (trauma) / birth injury 
 Cerebral malformation 
 Stroke 
 Vasculitis – e.g. Systemic Lupus erythmetosis 
 Tumour (Primary or metastatic) 
 Conditions that might deprive the brain of oxygen – for example near drowning. 
 Infective causes: e.g. – meningitis, encephalitis, febrile convulsions etc. 
 Coeliac disease. 
 Metabolic conditions like hypoxia, low blood sugar, low or high salt, low 
magnesium or calcium etc. 
 
4. Other factors: 
 Exposure to lead, carbon mono oxide or other environmental toxins 
 Overdose or withdrawal or certain medications 
 Alcoholism 
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2.6 Pathophysiology 
At the cellular level, the two hallmark features of epileptic form activity are 
neuronal hyperexcitabilityAnd neuronal hyper synchrony. Hyper excitability refers to 
the heightened response of a neuron to Stimulation, so that a cell might fire multiple 
action potentials rather than single ones in response to a Synaptic input. Hyper 
synchrony reflects increased neuron firing within a small or large region of cortex, 
with cells firing in close temporal and spatialproximity.While there are differences in 
the mechanisms that underlie focal versus generalized seizures, at a simplistic level it 
is still useful to view any seizure activity as a perturbation in the normal balance 
between inhibition and excitation in a localized region, in multiple discrete areas 
(seizure “foci”), or throughout the whole brain (Figure 1.2). 
 
This imbalance likely involves a combination of increased excitation and 
decreased inhibition (Table 1.1).In addition to the traditional concept of 
excitation/inhibition imbalance, novel pathophysiological mechanisms for the 
epilepsies are also being discovered. For example, in febrile seizures, release of 
inflammatory mediator’s such as cytokines could contribute to neuronal hyper 
excitability, an observation that might open new avenues of treatment. 
 
Figure 1.1. 
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Coronal sections of the brain indicating patterns of seizure origination and 
spread. (A) Primary Generalized seizure begins deep in brain (thalamus) with spread 
to superficial cortical regions (arrows). (B) Focal onset seizure begins in one area of 
the brain (star) and may spread to nearby or distant brain regions. (C) A focal onset 
seizure “secondarily generalizes” by spreading first to thalamus (left panel) then to 
widespread cortical regions (right panel). 
 
Pathophysiology 
 
Figure 1.2. Simplified scheme indicating that seizure generation results from 
increased excitation (E), decreased inhibition (I), or both. Examples of intracellular 
recordings from normal and epileptic neurons are drawn next. 
 
 The normal brain contains billions of neurons activated at different time, i.e., 
asynchronous firing. The inhibitory feedback mechanisms in the normal brain 
regulate the frequency of firing of individual neurons and prevent synchronization. 
When inhibitory feedback defective, large number of cells in a given area of the brain 
fire at the same time and produce a self – regenerative electrical focus, such area is 
called ‘epileptic focus’. 
 Such foci may be cortical or sub – cortical and their spread to normal brain 
tissue is inhibited by inhibitory mechanisms. Factors which themselves can not 
initiate seizures may trigger off the abnormal focus or permit the spread of activity to 
the normal brain Such factors, rapid blinking of eyes or other rhythmic photic 
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stimulation, spread of the abnormal electrical activity to the normal brain tissue 
causes generalized seizures. 
 A seizure is traceable to an unstable cell membrane or its Surrounding cells. 
 An abnormality of potassium conductance, a defect in the voltage-sensitive 
calcium channels or a deficiency in the membrane ATPase result in seizure. 
 Normal neuronal activity depends on normal functioning of excitatory and 
inhibitory neurotransmitters. Also based on adequate supply of oxygen, 
glucose, sodium, potassium, chloride, calcium and amino acids. 
Examples : 
 Excitatory : Glutamate, aspartate, acetyl choline, histamine-releasing factor, 
purines, peptids, cytokines and steroid hormones. 
 Inhibitory : Dopamine, Gamma amino butyric acid.   
 
 Neurons are interconnected in complex network in which each individual 
neurone is linked through synapses with hundreds of others. A small electrical current 
is discharged by neurons to release  neurotransmitters at synaptic levels to permit  
communication with each other. Neurotransmitters fall into two basic categories: 
inhibitory or excitatory. Therefore, a neurone discharging can either excite or inhibit 
neurons connected to it. An excited neurons will activate the next neurone whereas an 
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inhibited neurone will not. In this manner, information is conveyed, transmitted and 
processed throughout the central nervous system. 
 A normal neurone discharges repetitively at a low baseline frequency, and it is 
the integrated electrical activity generated by the neurons of the superficial layers of 
the cortex that is recorded in a normal EEG. If neurons are damaged, injured or suffer 
a chemical or metabolic insult, a change in the discharge pattern may develop. In the 
case of epilepsy, regular low – frequency discharges are replaced by bursts of high – 
frequency discharges usually followed by periods of inactivity.    
 
Mutations in several genes have been linked to some type of epilepsy. Several genes 
that code for protein subunits of voltages – gated and ligand –gated ion channels have 
been associated with generalized epilepsy and infantile seizure syndromes.  
 Several ligand – gated ion channels have been linked to some types of frontal 
and generalized epilepsies. Epilepsy – related mutations in some non – ion channel 
genes have also been identified.  
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Trips and tricks 
The best practice is to use a single agent (monotherapy) to avoid side effects 
due to multiple AEDs. If it is necessary to treat apatient with more than one AED, 
drugs with differing mechanisms of action should be chosen to minimize adverse 
effects andDrug–drug interactions 
 
2.7 Signs and symptoms 
Epilepsy is characterized by a long-term risk of recurrent seizures. These 
seizures may present in several ways depending on the part of the brain involved and 
the person's age 
 
Symptoms of Simple Partial Seizures 
Symptoms may be motor, sensory, psychic (states of consciousness), and/or 
autonomic (involuntary activity controlled by the autonomic nervous system). There 
is no impairment of consciousness in simple partial seizures. While there is a wide 
range of potential signs and symptoms, for most patients symptoms are stereotypical. 
 
 Alternating contraction and relaxation of muscle groups 
 Eye movements and turning of the head to the same side 
 Asymmetrical posturing of the limbs 
 Speech arrest, vocalization 
Sensory symptoms include the following: 
 Seeing flashes of lights or colors, illusions and hallucinations 
 Hearing humming, buzzing, hissing noises 
 Experiencing unpleasant odors and tastes 
 Dizziness, light headedness 
Autonomic signs and symptoms include the following 
 Borborygmi (rumbling noises produced by gas in the intestines) 
 Flushing 
 Incontinence 
 Nausea, vomiting 
 Piloerection (goose bumps) 
 Pupillary dilation 
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 Sweating 
 Tachycardia (rapid heart rate) 
 
Psychic symptoms include the following: 
 Detachment, depersonalization 
 Dreamy state 
 Memory distortion: flashback, deja vu (feeling that one has seen something 
before), dejaentendu (feeling that one has heard something before), jamais vu 
(feeling that one has never seen something that is familiar), jamaisentendu 
(feeling that one has never heard something that is familiar), panoramic vision 
(rapid recall of past events) 
 Time distortion 
 Unprovoked emotion: fear, pleasure, displeasure, depression, anger, elation, 
ereoticism 
 
2.8 Diagnosis of Epilepsy  
You should see a doctor if you have had a possible seizure or similar event. 
Sometimes it is difficult for a doctor to confirm that you have had a seizure. The most 
important part of confirming the diagnosis is the description of what happened. Other 
conditions can look like seizures - for example, faints, panic attacks, collapses due to 
heart problems, breath-holding attacks in children. 
 
Therefore, it is important that a doctor should have a clear description of what 
happened during the event. It may be that a person who witnessed your seizure may 
be able to give a more accurate description of what happened during your seizure. 
There is no one test to confirm a diagnosis of epilepsy. However, tests such as brain 
scans, an electroencephalogram (EEG - brainwave recordings) and blood tests may 
help to make a diagnosis. 
 A brain scan - usually a magnetic resonance imaging (MRI) scan or computed 
tomography (CT) scan - shows the structure of different parts of the brain. This 
may be performed in some people. 
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 Electroencephalograph (EEG). 
 
  This test records the electrical activity of the brain. Special stickers are placed 
on various parts of the scalp. They are connected to the EEG machine. This amplifies 
the tiny electrical messages given off by the brain and records their pattern on paper 
or computer. The test is painless. Some types of seizure produce typical EEG patterns. 
However, a normal recording does not rule out epilepsy and not all EEG 
abnormalities are related to epilepsy. 
 Blood tests and other tests may be advised to check on your general well-being. 
They may also look for other possible causes of the event. 
Although helpful, tests are not foolproof. It is possible to have epilepsy with 
normal test results. Also, if an abnormality is found on a brain scan, it does not 
prove that it causes seizures. 
 Video EEGS also demonstrates what patient was doing when the seizure 
occurred and  how the  seizure changed  his behaviour. 
Other diagnosis: 
1. Magnetic resonance  imaging (MRI) 
2. Positron emission tomography (PET) 
3. Single photon emission tomography (SPECT) 
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2.9 MANAGEMENT AND TREATMENTS FOR EPILEPSY 
NON PHARMACOLOGICAL 
First aid 
 
 Rolling a person with an active tonic-clonic seizure onto their side and into the 
recovery position helps prevent fluids from getting into the lungs.[46]  
 Putting fingers, a bite block or tongue depressor in the mouth is not 
recommended as it might make the person vomit or result in the rescuer being 
bitten.  
 Efforts should be taken to prevent further self-injury. Spinal precautions are 
generally not needed. 
 If a seizure lasts longer than 5 minutes or if there are more than two seizures in 
an hour without a return to a normal level of consciousness between them, it is 
considered a medical emergency known as status epilepticus. This may require 
medical help to keep the airway open and protected; a nasopharyngeal airway 
may be useful for this.  
 At home the recommended initial medication for seizure of a long duration is 
midazolam placed in the mouth. Diazepam may also be used rectally.  
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 In hospital, intravenous lorazepam is preferred. If two doses of 
benzodiazepines are not effective, other medications such as phenytoin are 
recommended.  
 Convulsive status epilepticus that does not respond to initial treatment 
typically requires admission to the intensive care unit and treatment with 
stronger agents such as thiopentone or propofol.  
 
Prevention 
While many cases are not preventable, efforts to reduce head injuries, provide 
good care around the time of birth, and reduce environmental parasites such as the 
pork tapeworm may be effective. Efforts in one part of Central America to decrease 
rates of pork tapeworm resulted in a 50% decrease in new cases of epilepsy. 
 
Management 
 
 
Epilepsy is usually treated with daily medication once a second seizure has 
occurred,but for those at high risk, medication may be started after the first seizure. In 
some cases, a special diet, the implantation of a neurostimulator, or neurosurgery may 
be required. 
 
PHARMACOLOGICAL  
Medication 
Epilepsy cannot be cured with medication. However, with the right type and 
strength of medication, the majority of people with epilepsy do not have seizures. The 
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medicines work by stabilising the electrical activity of the brain. You need to take 
medication every day to prevent seizures.  
One medicine can prevent seizures in most cases. A low dose is usually started 
at first. The dose may be increased if this fails to prevent seizures. In some cases two 
medicines are needed to prevent seizures. 
 
 The decision when to start medication may be difficult. A first seizure may not 
mean that you have epilepsy, as a second seizure may never happen or may occur 
years later. The decision to start medication should be made by weighing up all 
the pros and cons of starting, or not starting, the medicine. It is unusual to start 
treatment after a first seizure. A common option is to wait and see after a first 
seizure. If you have a second seizure within a few months, more are likely. 
 
 Medication is commonly started after a second seizure that occurs within 12 
months of the first. However, there are no definite rules and the decision to start 
medication should be made after a full discussion with your doctor. The type of 
treatment you will be given often depends on the type of seizures you have and 
also if you are taking any other medication. 
 
 The mainstay treatment of epilepsy is anticonvulsant medications, possibly for the 
person's entire life. The choice of anticonvulsant is based on seizure type, epilepsy 
syndrome, other medications used, other health problems, and the person's age 
and lifestyle. A single medication is recommended initially; if this is not effective, 
switching to a single other medication is recommended. Two medications at once 
is recommended only if a single medication does not work. In about half, the first 
agent is effective; a second single agent helps in about 13% and a third or two 
agents at the same time may help an additional 4%.About 30% of people continue 
to have seizures despite anticonvulsant treatment.[39] 
 
 There are a number of medications available. Phenytoin, carbamazepine and 
valproate appear to be equally effective in both partial and generalized seizures.[47] 
Controlled release carbamazepine appears to work as well as immediate release 
carbamazepine, and may have fewer side effects. In the United Kingdom, 
carbamazepine or lamotrigine are recommended as first-line treatment for partial 
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seizures, with levetiracetam and valproate as second-line due to issues of cost and 
side effects. Valproate is recommended first-line for generalized seizures with 
lamotrigine being second-line. In those with absence seizures, ethosuximide or 
valproate are recommended; valproate is particularly effective in myoclonic 
seizures and tonic or atonic seizures. If seizures are well-controlled on a particular 
treatment, it is not usually necessary to routinely check the medication levels in 
the blood. The least expensive anticonvulsant is phenobarbital at around $5 USD a 
year. The World Health Organization gives it a first-line recommendation in the 
developing world and it is commonly used there. Access however may be difficult 
as some countries label it as a controlled drug.[41] 
List of anti-epileptic drugs 
Anti-epileptic drugs (AEDs) are the main form of treatment for people with 
epilepsy. And up to 70% (7 in 10) people with epilepsy could have their seizures 
completely controlled with AEDs. There are around 26 AEDs used to treat seizures, 
and different AEDs work for different seizures. Here we explain what the different 
AEDs are, what type of seizures or epilepsy they are used for, as well as some 
essential information about average doses and common side effects. 
   There are three ways you can search for information about AEDs: 
 By the generic name of the AED 
 By the brand name of the particular type of AED or 
 By the type of seizure or seizures you have. 
Generic names 
 Acetazolamide 
 Carbamazepine 
 Clobazam 
 Clonazepam 
 Eslicarbazepine acetate 
 Ethosuximide 
 Gabapentin 
 Lacosamide 
 Lamotrigine 
 Levetiracetam 
 Nitrazepam 
 Oxcarbazepine 
 Perampanel 
 Piracetam 
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 Phenobarbital 
 Phenytoin 
 Pregabalin 
 Primidone 
 Retigabine 
 Rufinamide 
 Sodium valproate 
 Stiripentol 
 Tiagabine 
 Topiramate 
 Vigabatrin 
 Zonisamide 
Brand names (available as): 
 Carbogen modified release 
 Convulex 
 Desitrend 
 Diacomit 
 Diamox SR 
 Emeside 
 Epanutin 
 Epilim 
 Epilim Chrono 
 Epilim Chronosphere 
 Episenta (prolonged release) 
 Epival 
 Frisium 
 Fycompa 
 Gabitril 
 Inovelon 
 Keppra 
 Lamictal 
 Lyrica 
 Neurontin 
 Nootropil 
 Phenytoin Sodium Flynn 
 Rivotril 
 Sabril 
 Tapclob 
 Tegretol 
 Tegretol Prolonged Release 
 Topamax 
 Trileptal 
 Trobalt 
 Vimpat 
 Zarontin 
 Zebinix 
 Zonegran 
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Seizure types  
 Absence seizures (including typical and atypical absences): 
Acetazolamide | Clonazepam | Ethosuximide | Lamotrigine | Sodium valproate 
  
 Atonic seizures: 
Phenobarbital | Phenytoin | Primidone | Sodium valproate  
  
 Catamenial seizures (menstrual-related): 
Acetazolamide | Clobazam 
  
 Cluster seizures: 
Clobazam  
  
 Episodic disorders: 
Acetazolamide 
  
 Dravet syndrome (severe myoclonic epilepsy in infancy or SMEI): 
Stiripentol  
  
 Focal (partial) seizures: 
Acetazolamide | Carbamazepine | Clobazam | Clonazepam | Eslicarbazepine 
acetate | Gabapentin | Lacosamide | Lamotrigine | Levetiracetam | 
Oxcarbazepine | Perampanel | Phenobarbital | Phenytoin | Pregabalin | 
Primidone | Retigabine | Sodium valproate | Tiagabine | Topiramate | 
Vigabatrin | Zonisamide  
Focal (partial) seizures with secondary generalisation: 
Gabapentin | Lacosamide | Levetiracetam | Perampanel | Phenobarbital | Phenytoin | 
Pregabalin | Primidone | Retigabine | Sodium valproate | Tiagabine |Topiramate | 
Vigabatrin| Zonisamide 
 
 Focal seizures with secondary generalised tonic clonic seizures: 
Carbamazepine | Eslicarbazepine acetate | Lamotrigine | Oxcarbazepine 
 Infantile spasms: 
Nitrazepam | Sodium valproate | Vigabatrin 
Juvenile Myoclonic Epilepsy (seizures related to): 
Levetiracetam  
 Lennox-Gastaut syndrome (seizures related to): 
Lamotrigine | Rufinamide | Topiramate  
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Menstrual-related (catamenial seizures): 
 
 Myoclonic seizures: 
Clonazepam | Ethosuximide | Phenobarbital | Phenytoin | Primidone | 
Piracetam | Sodium valproate  
 Myoclonic seizures in Juvenile Myoclonic Epilepsy: 
Tonic seizures: 
Phenobarbital | Phenytoin | Primidone | Sodium valproate  
 Tonic clonic seizures: 
Acetazolamide | Carbamazepine | Clobazam | Clonazepam | Eslicarbazepine acetate 
| Lamotrigine | Phenobarbital | Phenytoin | Primidone | Sodium valproate | 
Topiramate 
Tonic clonic seizures in severe myoclonic epilepsy in infancy (SMEI or Dravet 
syndrome): 
West Syndrome with Tuberous Sclerosis: Vigabatrin 
Adverse effect  
 Mood changes 
 Sleepiness 
 Unsteadiness 
 Rashes,  
 Liver toxicity 
 Suppression Of The Bone Marrow 
 
 
Slowly stopping medications may be reasonable in some people who do not 
have a seizure for two to four years; however, around a third of people have a 
recurrence, most often during the first six months. Stopping is possible in about 70% 
of children and 60% of adults 
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Some points about medication for epilepsy include the following: 
 Ask your doctor how long treatment is likely to be advised. This will vary from 
case to case. If you have not had seizures for several years, you may wish to try 
stopping medication. However, this depends on your particular type of epilepsy, 
as some types will need medication for life. Your life circumstances may 
influence the decision about stopping medication. For example, if you have 
recently regained your driving licence, the risk of losing it again for a year if a 
seizure occurs may affect your decision. However, if you are a teenager who has 
been free of seizures for some years, you may be happy to take the risk. 
 Although the list of possible side-effects for each medicine seems long, in 
practice, most people have few or no side-effects, or just minor ones. Ask your 
doctor which side-effects are important to look out for. If you develop a 
troublesome side-effect it may be dose-related, or may diminish in time. 
Alternatively, a switch to another medicine may be advised. 
 Medicines which are used for other conditions may interfere with medication for 
epilepsy. If you are prescribed or buy another medicine, remind your doctor or 
pharmacist that you take medication for epilepsy. Even things like indigestion 
medicines may interact with your epilepsy medication, which may increase your 
chance of having a seizure. 
 Some medicines for epilepsy interfere with the contraceptive pill. A higher-dose 
pill or an alternative method of contraception may be needed. 
 Tell your doctor if you intend to become pregnant. Pre-conception counselling is 
important for women with epilepsy. 
 If you have epilepsy and take medication, you are exempt from prescription 
charges for all your prescriptions. You need an exemption certificate. You can 
get this from your pharmacist. 
 
OTHER TREATMENTS FOR EPILEPSY 
 Surgery to remove a small part of the brain which is the underlying cause of the 
epilepsy. This is only a suitable option if your seizures start in one small area of 
your brain (this means it is only possible for a minority of people with epilepsy). It 
may be considered when medication fails to prevent seizures. However, there are 
risks from operations. Only a small number of people with epilepsy are suitable 
for surgery and, even for those who are, there are no guarantees of success. 
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Surgical techniques continue to improve and surgery may become an option for 
more and more people in the future. 
 Vagal nerve stimulation is a treatment for epilepsy, where a small generator is 
implanted under the skin below the left collarbone. The vagus nerve is stimulated 
to reduce the frequency and intensity of seizures. This can be suitable for some 
people with seizures that are difficult to control with medication. 
 The ketogenic diet is a diet very high in fat, low in protein and almost 
carbohydrate-free which can be effective in the treatment of difficult-to-control 
seizures in children. 
 Complementary therapies such as aromatherapy may help with relaxation and 
relieve stress; however, they have no proven effect on preventing seizures. 
  
2.10 PROGNOSIS  
The success in preventing seizures by medication varies depending on your 
type of epilepsy. For example, if no underlying cause can be found for your seizures 
(idiopathic epilepsy), you have a very good chance that medication can fully control 
your seizures. Seizures caused by some underlying brain problems may be more 
difficult to control. 
 
The overall outlook is better than many people realise. The following figures 
are based on studies of people with epilepsy, which looked back over a five-year 
period. These figures are based on grouping people with all types of epilepsy together, 
which gives an overall picture: 
 About 5 in 10 people with epilepsy will have no seizures at all over a five-year 
period. Many of these people will be taking medication to stop seizures. Some 
will have stopped treatment having had two or more years without a seizure 
while taking medication. 
 About 3 in 10 people with epilepsy will have some seizures in this five-year 
period but far fewer than if they had not taken medication. 
 So, in total, with medication, about 8 in 10 people with epilepsy are well 
controlled with either no, or few, seizures. 
 The remaining 2 in 10 people experience seizures, despite medication. 
 A very small number of people with epilepsy have sudden unexplained death. 
The exact cause of this is unknown. However, it may be related to a change in the 
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breathing pattern or to abnormal heart rhythms during a seizure. This is rare and 
the vast majority of people with epilepsy fully recover following each seizure. 
 
A trial without medication may be an option if you have not had any seizures 
over 2-3 years. If a decision to stop treatment is made, a gradual reduction of the dose 
of medication is usually advised over several months. You should never stop taking 
medication without discussing it with a doctor. 
 
2.11 INVESTIGATIONS 
 Drug Therapy 
Two Type of drug therapy is followed  
1. Mono Therapy 
2. Add on Therapy 
 
1. MONOTHERAPHY 
Antiepileptic Drug Monotherapy 
 Antiepileptic drug (AED) mono therapy is the preferred initial management 
approach in epilepsy care, since most patients may be successfully managed 
with the first or second mono therapy utilized.  
 The rationale and evidence supporting preferential use of mono therapy when 
possible and guidelines for initiating and successfully employing AED mono 
therapy. Suggested approaches to consider when patients fail mono therapy 
include substituting a new AED mono therapy, initiating chronic maintenance 
AED poly therapy, or pursuit of non-pharmacologic treatments such as epilepsy 
surgery or vagus nerve stimulation.  
 Reducing AED poly therapy to mono therapy frequently reduces the burden of 
adverse effects and may also improve seizure control. AED mono therapy 
remains the optimal approach for managing most patients with epilepsy.[59] 
Introduction 
Epileptic seizures have been observed since antiquity . Treatment preferences 
generally favoured poly therapy prior to the evolution of modern antiepileptic drugs 
(AEDs). In the early 1900s, phenobarbital and the ketogenic diet were used to manage 
epilepsy. Throughout the earlier 20th century, the standard AEDs (phenytoin, 
phenobarbital, primidone, valproic acid, carbamazepine, and ethosuximide) were 
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often combined in poly therapy use, due to the pervasive belief that polytherapy was 
more efficacious than mono therapy. However, during the 1970s, several studies 
suggested that mono therapy was equally efficacious, less toxic, and more tolerable 
than poly therapy[60]. Since then, most epilepsy experts have advocated mono therapy 
as the preferred approach in epilepsy, although poly therapy is sometimes still 
necessary. The evidences favoring initial mono therapy and suggests methods to 
maintain mono therapy or reduce poly therapy to mono therapy when possible. 
 
THE RATIONALE FAVORING MONOTHERAPY 
Since the early 1990s, the second-generation AEDs, felbamate, gabapentin, 
lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, zonisamide, and 
pregabalin, have become available. Recently, the seemingly ever increasing 
armamentarium of AEDs has seen two additional newer (“third-generation”) AEDs 
released, lacosamide and rufinamide. Advantages of most newer AEDs include a 
more desirable safety profile and fewer adverse effects and drug interactions than 
their predecessors. Recent pivotal clinical trials have provided evidence to support 
monotherapy use of second-generation AEDs[64]. Current treatment guidelines 
recommend monotherapy in most cases because data indicate similar efficacy and 
better patient tolerability compared to polytherapy[68]. Polytherapy may only 
minimally increase seizure control and can substantially increase AED toxicity,drug 
interactions, seizure aggravation[71], comorbid depression, risk of sudden unexplained 
death in epilepsy patients (SUDEP), noncompliance, and cost. Polytherapy and 
seizure burden were the two main causes of quality of life impairment in one recent 
survey of epilepsy patients. 
 
WHO BENEFITS MOST FROM MONOTHERAPY 
While mono therapy is preferable for most patients with epilepsy, mono 
therapy is particularly desirable for certain special patient populations, including 
women, elderly, and patients with co-morbid conditions (who are at increased risk for 
AED toxicity and drug interactions)[68]. Compared to poly therapy, mono therapy 
reduces the potential for adverse drug interactions. Hepatic and renal dysfunction 
significantly impacts the metabolism and elimination of many AEDs, which may 
reduce tolerability and safety of continued use. Pregnant women taking two or more 
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AEDs are at substantially increased risk of fetal malformations (3% versus 15%) than 
mothers receiving mono therapy . 
 
EVIDENCE SUPPORTING PREFERENTIAL MONOTHERAPY IN 
EPILEPSY 
The majority of patients with epilepsy respond to treatment with mono 
therapy; 47% of patients become seizure-free with the first AED tried, and another 
13% achieve freedom from seizures with the second mono therapy trial. 
 
While available evidence is central in determining whether an AED is 
effective for mono therapy usage, FDA approval and indication generally guide how 
an AED will be prescribed. First-generation AEDs were “grandfathered” by the FDA, 
receiving approval for mono therapy for a particular seizure type without requirement 
to satisfy current rigorous approval requirements. The majority of second-generation 
AEDs are approved only as adjunctive therapies. Since few comparator studies are 
funded by industry, government agencies should become involved in conducting 
additional comparative clinical trial studies, and independent groups  should be 
persuaded to collect data from historically treated and control patients. 
 
Currently, four second-generation AEDs are FDA approved for use as mono 
therapy, with some limitations; these are oxcarbazepine, lamotrigine, topiramate, and 
felbamate. In four randomized, controlled, blinded trials, oxcarbazepine demonstrated 
efficacy as mono therapy in patients with partial seizures. Lamotrigine is currently 
approved as mono therapy when converting from an enzyme-inducing AED or 
valproate but not for de novo or initial mono therapy . However, lamotrigine should 
be used with caution in persons under the age of 16 due to a higher incidence of a 
potentially life-threatening rash in pediatric patients, and patients receiving concurrent 
valproic acid or who receive inappropriately fast initial titration of lamotrigine are 
also at heightened risk of serious rash. Topiramate is indicated as initial mono therapy 
in adults and children aged 10 years and older with partial onset or primary 
generalized seizures; efficacy was established in both a large, double-blind, dose-
controlled study and a second large trial comparing two doses of topiramate with 
standard comparators carbamazepine and valproate[72]. Felbamate also has evidence 
for monotherapy use in partial-onset seizures; however, severe idiosyncratic toxicities 
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limit its use. Additionally, gabapentin possesses adequate evidence for confident use 
as monotherapy in treatment of partial-onset seizures, although it lacks formal FDA 
approval for this indication. 
 
Among the second-generation AEDs approved for monotherapy use, few 
comparator trials have been conducted. Gabapentin and lamotrigine have been shown 
to be comparably effective and tolerable in two large prospective trials, and were 
more tolerable than carbamazepine in elderly with newly diagnosed epilepsy. A large, 
naturalistic, unblinded controlled trial recently demonstrated superior efficacy  of 
lamotrigine as compared to carbamazepine, oxcarbazepine, and topiramate. 
 
The other second-generation and third-generation AEDs have not been FDA 
approved for monotherapy use since most lack an adequate level of evidence for this 
indication. However, the efficacy and tolerability of levetiracetam monotherapy for 
treatment of partial-onset seizures has been confirmed in a recent large, prospective, 
comparator trial against carbamazepine.  
 
GUIDELINES FOR AED MONOTHERAPY 
Given the complexity and expansive body of evidence concerning AED 
therapy in the medical literature and limitations in practical application of this 
literature to actual patients, practice guidelines and expert surveys are valuable tools 
to assist clinicians in applying evidence based practice for patients with epilepsy. 
Practice guidelines are available to assist practitioners in the management of new-
onset and refractory epilepsy and epilepsy in women. The American Academy of 
Neurology/American Epilepsy Society (AAN/AES) Practice Guidelines for the 
treatment of new-onset epilepsy identified gabapentin, lamotrigine, oxcarbazepine, 
and topiramate as possessing Class I evidence (prospective study, blinding, statistical 
population-based sample, and patients studied concurrently and early in the course of 
therapy) for use as monotherapy in the treatment of new-onset partial or mixed 
seizures. In the treatment of epilepsy in women state that in women with epilepsy 
(WWE), monotherapy is recommended during the reproductive years to reduce the 
risk of teratogenicity seen with polytherapy . 
A recent survey of epilepsy experts found that lamotrigine, levetiracetam, and 
valproic acid are preferred AED choices for monotherapy in the treatment of 
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generalized tonic-clonic, absence, and myoclonic seizures . Previous survey results 
were compared to the current survey, and, overall, valproic acid is still the drug of 
choice for each of these seizure types, except for absence seizures, where 
ethosuximide remains the preferred AED. Many practitioners chose lamotrigine and 
topiramate as first-line treatment for generalized tonic-clonic seizures. 
 
HOW TO INITIATE MONOTHERAPY 
Practical tenets for achieving successful monotherapy in new-onset epilepsy 
management include the following:  
1. Select an efficacious AED for the specific seizure type;  
2. Choose an AED with a tolerable adverse effect and toxicity profile. 
3. Titrate the AED slowly to the desired dose, taking into account the patient’s 
response to treatment.  
 
If the first AED monotherapy is ineffective, adding a second AED, then tapering 
and discontinuing the ineffective AED, is the preferred approach. When switching 
AEDs, selecting an agent with a different MOA may increase the likelihood of a 
successful treatment response. If the second sequential AED monotherapy is 
ineffective, an adjunctive AED with a different and potentially complementary MOA 
should be considered for use in adjunctive polytherapy. Since approximately 35% of 
patients with epilepsy will not respond to monotherapy, most refractory patients 
become candidates for polytherapy. Polytherapy with lower or moderate dosages of 
two AEDs may also sometimes be preferred for management of refractory patients 
who have dose-limiting neurotoxic adverse effects with high-dose monotherapy. 
 
Before initiating treatment, patients with epilepsy should undergo a thorough 
medical evaluation to determine seizure type and consider baseline patient 
characteristics that may influence the decision of whether treatment is necessary and, 
if so, which AED may be the most logical choice. Evaluation to determine the 
patient’s epilepsy syndrome begins with a thorough clinical history, including a 
detailed description of the seizure semiology, an awake and asleep 
electroencephalogram (EEG), and a brain magnetic resonance image (MRI). A 
standard brain MRI is adequate in newly diagnosed epilepsy where the priority is to 
exclude underlying serious symptomatic pathologies, such as arteriovenous 
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malformations or neoplasms. However, when feasible, available, and of reasonable 
cost, it is advantageous to consider obtaining brain MRI with a volumetric seizure-
protocol study in patients with suspected partial-onset seizures, given better 
identification of subtle mesial temporal lobe pathologies such as hippocampal 
sclerosis or malformations of cortical development that may impact on prognosis for 
drug responsiveness, as well as future decisions regarding surgical triage if the patient 
becomes refractory to AEDs. 
 
Educating the patient about epilepsy, AED compliance, and seizure first-aid is 
important for ensuring successful therapy. AED selection is determined by seizure 
type, patient medical history, and concurrent medications. For partial epilepsy, any 
approved AED could be considered for use (except ethosuximide, which is ineffective 
for partial-onset seizure treatment). In idiopathic or symptomatic generalized 
epilepsies, as well as for ambiguous or unknown epilepsy syndromes, a broad-
spectrum AED should be preferentially utilized given the potential to treat  other 
potentially associated generalized seizure-types in generalized epilepsies (i.e., absence 
and myoclonic seizures in idiopathic generalized epilepsies, or tonic seizures in 
symptomatic generalized epilepsy). 
 
After AED selection  has been made, starting with a low dose and gradually 
titrating to a moderate and presumably effective dose is a reasonable strategy, since 
titration to higher doses. A more rapid titration may be necessary in selected patients 
who have had multiple recent seizures. Maximizing the dose is only recommended in 
patients who do not respond to moderate doses. At each patient visit, it is necessary to 
conduct a detailed assessment of AED therapy, including adverse effects and 
compliance. Utilizing a quantitative survey of patient’s perceived adverse effects such 
as the adverse events profile (AEP) has been prepared alter antiepileptic drug 
therapies to for improving quality of life.  
 
WHY ARE SOME PATIENTS REFRACTORY TO MONOTHERAPY 
The efficacy of currently available AEDs is limited to reduction of seizure 
frequency, and no AED has yet been proven to impact the pathophysiology of 
epilepsy itself. Currently, there is no convincing evidence that any of the available 
AEDs are anti-epileptogenic, nor has any AED been shown to favorably impact the 
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long-term outcome of epilepsy Yet, prescribing an AED after a second or third seizure 
event is the accepted practice standard, based on logic derived in part from 
epidemiologic studies of the natural history of new onset unprovoked seizures that 
confirm a greatly increased risk for further seizure recurrence following the 
occurrence of a second unprovoked seizure. The desired short-term outcomes of 
epilepsy management are seizure freedom, seizure control when complete seizure 
freedom is not possible, and maximizing patient quality of life, given that the 
complications of untreated seizure activity are increased risk of injury and mortality, 
cognitive and behavioral abnormalities, and social disadvantage. Currently, there is no 
AED for the treatment of epilepsy that is completely effective, without adverse 
effects, and efficacious for all patients. Of the older AEDs, carbamazepine was shown 
to be the most effective and tolerable AED in two pivotal clinical trials; thus, it 
became the standard to which developing AEDs have been compared,  although 
carbamazepine itself has never been compared to placebo or demonstrated efficacy in 
an active control-designed study. Most studies have shown that newer AEDs have 
equivalent efficacy to that of carbamazepine, but several newer AEDs have superior 
tolerability including lamotrigine and gabapentin[72]. However, recently published 
comparator trials of newer AEDs against a sustained release form of carbamazepine 
have shown relatively equivalent tolerability, suggesting that immediate release forms 
of carbamazepine may be less tolerable and sustained release forms of carbamazepine 
are equally tolerable to newer AEDs  
 
Monotherapy is preferred when treating epilepsy, although previous reports 
indicate that polytherapy was sometimes the standard of care and given routinely as 
initial treatment.1 Polytherapy began to be questioned shortly after studies showed 
that 50% to 75% of patients who started on monotherapy remained seizure free for at 
least 1 year and that monotherapy is equally or more effective, better tolerated, and 
associated with fewer drug interactions compared with polytherapy. Other advantages 
of monotherapy include better compliance, lower costs, and improved quality of life.  
 
The efficacy of conventional antiepileptic drugs (AEDs), including phenytoin, 
carbamazepine, phenobarbital, and valproate, as monotherapy is accepted, but 
efficacy of monotherapy with some of the newer AEDs has been established in well-
controlled trials. To protect patients from the potential dangers of a noneffective agent 
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used as monotherapy, many newer medications were initially studied as adjunctive 
therapy in refractory patients, and when efficacy and tolerability as adjunctive 
treatments were established, newer medications were then studied as monotherapy.  
 
There is a long tradition of treating epilepsy patients with two or more AEDs. 
However, in the past decade monotherapy has emerged as the ultimate treatment 
strategy for both newly-diagnosed and long-term patients because of fewer side 
effects, better compliance, less teratogencity and lower cost. Furthermore, the 
evidence does not exist that additional drugs improve seizure control in most patients. 
Obtaining FDA approval for monotherapy use is particularly important for the 
advantages of better tolerability, improved safety, less teratogenicity, and simpler 
pharmacokinetics than the older drugs.  
 
Considering the ethical issues of placebo-controlled trials and the benefits of 
monotherapy treatment, however, there was considerable support at the workshop for 
consideration of active-control equivalence trials for monotherapy approval of AEDs. 
This resulted in substantial debates between participants and representatives from the 
FDA as to this approach. The FDA did indicate willingness to considering 
experiences from historical controls, if the data exist to support them. These data 
would have to be based on previous trials of active control vs. placebo under similar 
conditions with respect to study population, endpoints, dose of active control and 
other important design features. 
 
The workshop ended with the draft of a brief consensus statement. A task 
force will be set up to look at the issue of historical control and to see what data exist. 
Most participants indicated that the workshop had been a good start in addressing the 
monotherapy issue. 
 
EVALUATING MONOTHERAPY CLINICAL TRIALS 
The long-term, randomized, double-blind, placebo-controlled clinical trial of 
monotherapy in epilepsy is generally untenable for new AEDs because of possible 
harm arising from withholding active treatment. Randomized active-control trials 
comparing monotherapy with a test medication and monotherapy with a reference 
medication in newly diagnosed patients allowing assessment of efficacy and 
tolerability under conditions approximating clinical use. Because a new drug would 
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not be expected to surpass the high (70%-80%) seizure remission rates achieved with 
established agents, demonstration of comparable efficacy of the test and reference 
medications is interpreted as evidence of the test medication’s efficacy. 
 
Several alternative study designs compare test medication with a suboptimal 
treatment, which may be a nontherapeutic dose of the same drug, a different drug, or a 
placebo. Presurgical trials compare high doses of a test AED with placebo in patients 
with refractory seizures who need to discontinue their current therapy for evaluation 
before epilepsy surgery. These trials are of short duration because of the risks patients 
are exposed to in the placebo arm (ie, no AED treatment). This trial design compares 
the seizure frequency between the study drug and placebo, just as in other placebo-
controlled trials. In open-label substitution trials, a high dosage of the test medication 
is compared with a suboptimal dosage of the same drug or with either a suboptimal 
drug or an effective dosage of a different one.11 When ethically feasible, a placebo 
group sometimes takes the place of the active comparator in substitution trials. 
 
These alternative study designs require relatively few patients to demonstrate 
statistically significant effects of treatment. However, because of short duration and 
lack of flexibility for titrating doses to optimum levels, the practical relevance of data 
derived from these studies is limited. 
 
 
2. ADD ON THERAPY 
Adequate control of partial-onset epilepsy often requires polypharmacy, either 
due the to less than ideal efficacy of one antiepileptic drug (AED)  or due to side 
effects caused by the initial AED . Up to one-third of patients with partial-onset 
epilepsy will require treatment with more than one AED. 
 
The ideal medical management of epilepsy is based on tailoring each patient’s 
regimen to his or her seizure type, comorbidities, lifestyle, and history of medication 
side effects. Therefore, a greater number of potential treatments offers greater options 
for any given patient to be treated with the best combination of medications. In recent 
years, many new AEDs have become available for add-on therapy for partial-onset 
epilepsy of the newer AEDs, those that are US Food and Drug Administration (FDA)-
approved for the adjunctive treatment of partial-onset epilepsy include 
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felbamatetigabine, lamotrigine, pregabalin, gabapentin, topiramate, oxcarbazapine, 
zonisamide, and levetiracetam. An add-on AED should ideally have a clean 
pharmodynamic and phamcokinetic profile to minimize drug interactions and side 
effect profile. The newer AEDs are generally safer than the first-generation AEDs 
and, with the exception of Felbamate, do not require routine blood monitoring. All of 
the newer AEDs are category C in terms of use in females who want to have children, 
although a patient who is planning a pregnancy should aim for the lowest number of 
AEDs given at the lowest dose. 
 
The physician’s armamentarium to treat epilepsy has been significantly 
improved by the increasing number of new AEDs, all of which can be used as add-on 
therapy. In treating a patient, one must consider not only efficacy, but also 
comorbidities, potential adverse effects, and dosing schedules. The real-world dosing 
of AEDs as add-on therapy does not need to follow the package insert dosing 
recommendation derived from clinical trial titration schedule because the mantra of 
starting with a lower dose and slowly increasing it will lead to better tolerability and 
higher retention in most cases, especially in the elderly. With a greater understanding 
of the strengths and weaknesses of each AED, physicians can use each medication 
optimally for each patient.  
 
Levetiracetam 
Levetiracetam is approved as adjunctive therapy in the treatment of partial-
onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary 
generalized tonic-clonic seizures in adults and children ≥6 years of age. There is now 
an intravenous form of leveitracetam available. Levetiracetam binds a brain-specific 
binding site presynatpic vesicle protein SV2A, and has been shown to inhibit 
Ca2+ release and other possible neurotransmitters(73). 
 
Levetiracetam has no known significant drug interactions. It is an AED that is 
generally well tolerated. The most significant adverse effects are somnolence, 
asthenia, and dizziness. A drug-specific adverse effect is irritability, which seems to 
be more common in patients with underlying behavioral issues and may be 
doserelated. No serious acute idiosyncratic reactions were reported. 
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CLOBAZAM 
 
Clobazam (CLB) is in use for almost four decades since its introduction in 
1975. Its use has expanded from anxiety to epilepsy including Lennox-Gastaut 
syndrome (LGS) This broad spectrum antiepileptic prevents recurrence of febrile 
seizures also. According to a Canadian study, more than 10 per cent treatment 
refractory patients achieved seizure freedom with clobazam over a period of seven 
years. Despite being a benzodiazepine, clobazam has lower sedative effects. Adverse 
effects associated with clobazam, generally transient and dose-related, include 
somnolence, dizziness, mood changes, irritability, depression and aggression. 
 
Efficacy and safety of a drug are established through rigorous randomized 
controlled trials. Which especially play an important role in the pharmacotherapy of 
epilepsy. Though studies in Indian population have demonstrated the efficacy of CLB 
as monotherapy in adult patients and in refractory childhood epilepsy, data regarding 
the usage pattern, efficacy and safety of clobazam in different treatment regimens are 
limited.  
 
CONVERTING FROM POLYTHERAPY TO MONOTHERAPY 
Patients may begin receiving polytherapy while transitioning from one trial of 
monotherapy to another (transitional monotherapy), or because of two failed attempts 
with monotherapy (chronic polytherapy). In the first situation, eventual monotherapy 
is likely to result once the original AED is tapered off. However, in the latter case, 
patients may continue on multiple AEDs indefinitely. While receiving multiple AEDs, 
some patients may go into seizure remission, while other patients will continue to 
require sequential trials of additional AEDs). Patients who are appropriate candidates 
for tapering one or more AEDs are those who have been seizure free for 2 years or 
longer. For these patients, a slow taper is recommended, with dose reductions 
occurring weekly or every other week. Additionally, patients receiving unsuccessful 
polytherapy  should be considered for a further trial of monotherapy or additional 
AED sequencing.[55] 
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RATING SCALES 
1)Clinical Global Impressions (CGI) Scale is use to epilepsy treatment 
 
CLINICAL GLOBAL IMPRESSIONS (CGI) SCALE  
 CGI is a three item scale used to assess treatment response in epileptic 
patients. They are. 
 
 Severity of Illness 
It is rated on a seven – point scale (1=normal to 7=extremely ill) 
 Global Improvement 
It is a rated on a seven – point scale (1=very much improved to 7=very much 
worse) 
 Efficiency Index 
It is a four – point scale (from ‘none’ to ‘outweighs therapeutic effect’) 
The Severity of Illness item requires the clinician to rate the severity of the 
patients illness at the time of assessment, relative to the clinician’s past experience 
with patients who have the same diagnosis. Considering total clinical experience, a 
patient is assessed on severity of illness at the time of rating according to: normal 
borderline ill; mildly ill; moderately ill; markedly ill; severely ill; or extremely ill. 
 
The global improvement item requires the clinician to rate how much the 
patient’s illness has improved are worsened relative to a baseline state. Compared to 
condition at baseline, a patient’s illness is compared to change over time, and related 
according to: very much improved; much improved; moderately improved; minimally 
improved; no change; minimally worse; moderately worse; much worse; or very 
much worse. 
CGI SCALE BENEFITS 
 Robust – CGI has proved to be a robust measure of efficacy in drug treatment 
trials 
 Simplicity – the scale is clinically understandable 
 Sensitive to change 
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CGI SCALE CHALLENGES 
 Subjective – to a certain degree, severity of illness as rated on the CGI scale is 
based on the rater’s subjective views of symptom severity, which can vary 
between raters and make consistent interpretation of CGI scores problematic in 
practice. 
 Lack of structure – the CGI scale is administered at initial  patient assessment and 
at least once when treatment / change in treatment has been initiated. Additional 
assessments are conducted at the discretion of the clinician. Again, this implies a 
certain degree of subjectivity in terms of the timing and frequency of CGI 
assessment which may make retrospective interpretation difficult. 
 In – depth knowledge required – although the CGI scale is quickly administered, 
particularly for the global improvement scale it is paramount for the rater to know 
the patient. If a clinical history is not available, then the tool cannot be utilised. 
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3.1 PHENYTOIN (76_80) 
Phenytoin, sold under the brand name Dilantin among others, is an anti-
seizure medication. It is useful for the prevention of tonic-clonic seizures, partial 
seizures, but not absence seizures. The intravenous form is used for status epilepticus 
that does not improve with benzodiazepines. It may also be used for certain heart 
arrhythmias or neuropathic pain. It can be taken intravenously or by mouth. The 
intravenous form generally begins working within 30 minutes and is effective for 24 
hours. Blood levels can be measured to determine the proper dose. Phenytoin was first 
made in 1908 and found useful in seizures in 1936. It is on the World Health 
Organization's List of Essential Medicines, the most important medications needed in 
a basic health system. 
Brand names 
Dilantin, Phenytoin Sodium, Phenytoin Sodium, Extended Release, Phenytek 
Drug class(es): group I antiarrhythmics, hydantoin anticonvulsants. 
PHARMACOLOGICAL CLASSIFICATIONS: Anticonvulsants 
DESCRIPTION 
Chemical IUPAC Name: 5,5-diphenylimidazolidine-2,4-dione 
 
STRUCTURE 
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Chemical Formula: C15H12N2O2 
INDICATIONS: 
Phenytoin systemic is used in the treatment of: 
 Anxiety 
 Arrhythmia 
 Cluster-Tic Syndrome 
 Epilepsy 
 MyotoniaCongenita 
 Neurosurgery 
 Peripheral Neuropathy 
 Rheumatoid Arthritis 
 Seizures 
 Status Epilepticus 
 Trigeminal Neuralgia 
 
Mechanism of action 
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Phenytoin is believed to protect against seizures by causing voltage-dependent 
block of voltage gated sodium channels. This blocks sustained high frequency 
repetitive firing of action potentials. This is accomplished by reducing the amplitude 
of sodium-dependent action potentials through enhancing steady state inactivation. 
Sodium channels exist in three main conformations: the resting state, the open state, 
and the inactive state. 
Phenytoin binds preferentially to the inactive form of the sodium channel. 
Because it takes time for the bound drug to dissociate from the inactive channel, there 
is a time dependent block of the channel. Since the fraction of inactive channels is 
increased by membrane depolarization as well as by repetitive firing, the binding to 
the inactive state by phenytoin sodium can produce voltage-dependent, use-dependent 
and time-dependent block of sodium-dependent action potentials.  
The primary site of action appears to be the motor cortex where spread of 
seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, 
phenytoin tends to stabilize the threshold against hyperexcitability caused by 
excessive stimulation or environmental changes capable of reducing membrane 
sodium gradient. This includes the reduction of post-tetanic potentiation at synapses 
which prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin 
reduces the maximal activity of brain stem centers responsible for the tonic phase of 
generalized tonic-clonic seizures 
Clinical Pharmacology 
Phenytoin is an anticonvulsant with a primary site of action in the motor 
cortex. Environmental changes or excessive stimulation can cause a reduction in 
membrane sodium gradient. Phenytoin causes an efflux of sodium from neurons and 
therefore stabilises the threshold against over-activity in those brain stem centres 
responsible for the tonic phase of grand mal seizures 9. Absorption from 
gastrointestinal tract and intramuscular injection sites erratic. Phenytoin has high 
binding (85-90%) to plasma protein. Bilirubin displaces phenytoin from albumin 
binding sites resulting in higher percentage of unbound drug in plasma. Elimination 
via the kidney. Pharmacokinetics are dose-dependent over the therapeutic range and 
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unpredictable in the neonate. Relatively small margin between full therapeutic effect 
and a minimally toxic dose of phenytoin. 
 Pharmacokinetic data 
Bioavailability 70-100% oral, 24.4% for rectal and 
intravenous administration 
Protein binding 95%[1] 
Metabolism liver  
Onset of action 10 to 30 min (IV)[2] 
Biological half-
life 
10–22 hours[1] 
Duration of 
action 
24 hr[2] 
Excretion Primarily through the bile, urinary 
Dose and Administration 
1. Loading dose: 20 mg/kg by slow IV infusion over 60 minutes 5
.
 
2. Maintenance dose: 2-4 mg/kg/dose twice a day by slow IV infusion, or PO 6. 
Administer at a rate not faster than 1.0 mg/kg/minute 6. 
The maintenance dose needs to be monitored and adjusted according to blood 
levels. 
Contraindications 
1. Sinus rhythm bradycardia, sinoatrial or atrioventricular block. 
Precautions 
1. Known hypersensitivity to phenytoin. 
2. Neonates with jaundice, respiratory failure, hypotension or heart failure. 
3. Preterm infants, especially extreme immaturity. 
4. Neonates and infants with hepatic or renal impairment. 
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Drug Interactions 
Phenytoin may 
increase the 
levels of: 
Phenobarbitone. 
Phenytoin may 
decrease the 
levels or 
activity of: 
Paracetamol, caffeine, 
corticosteroids, diazoxide, digoxin, dopamine, fentanyl, fur
osemide, theophylline. 
Phenytoin 
levels may be 
decreased by: 
Phenobarbitone, rifampicin, theophylline. 
Phenytoin 
levels may be 
increased by: 
Fluconazole, ranitidine. 
Phenytoin 
levels may be 
altered by: 
Chlorpromazine, benzodiazepines. 
Phenytoin 
levels may be 
altered by: 
Interfere with thyroid function tests, and produce lower 
than normal values for metyrapone suppression tests. 
Possible Adverse Effects 
1. Injection is very alkaline –therefore may result in venous irritation and 
phlebitis. Avoid extravasation. 
2. Observe diluted solution, for crystal formation. 
3. Rapid administration may result in hypotension, CNS depression, cardiac 
arrhythmias, and impaired cardiac conduction. 
4. Gastrointestinal disturbances (nausea, vomiting, constipation). 
5. Overdosage may result in hypotension, coma, respiratory depression. 
Nystagmus may be an indication of toxicity. 
6. Possible interference of Vitamin D and folate metabolism. Megaloblastic 
anaemia. 
7. Hypersensitivity reactions eg. skin rashes. Bullous or purpuric rashes are 
indicators to withdraw therapy as they may be symptoms of rare but severe 
reactions eg. toxic epidermal necrolysis. 
8. Hyperglycaemia. 
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3.2 Carbamazepine:[81-84] 
Carbamazepine (CBZ), sold under the tradename Tegretol among others, is 
a medication used primarily in the treatment ofepilepsy and neuropathic pain. For 
seizures it works as well as phenytoin and valproate. It is not effective for seizures 
or myoclonic seizures. It may be used in schizophrenia along with other medications 
and as a second line agent in bipolar disorder. It is taken two to four times per day.  
Brand Name: 
Brandnames: Tegretol, Carbatrol, Tegretol,XR, Epitol 
Drug class(es): dibenzazepine anticonvulsants 
PHARMACOLOGICAL CLASSIFICATION: Anticonvulsants 
DESCRIPTION: 
Chemical IUPAC Name: 5H-dibenzo[b,f]azepine-5-carboxamide 
Chemical Formula:  C15H12N2O 
 
STRUCTURE 
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INDICATIONS: 
Carbamazepine systemic is used in the treatment of: 
 Bipolar Disorder 
 Cluster-Tic Syndrome 
 Cyclothymic Disorder 
 Diabetic Peripheral Neuropathy 
 Dystonia 
 Epilepsy 
 Occipital Neuralgia 
 Peripheral Neuropathy 
 Reflex Sympathetic Dystrophy Syndrome 
 Schizoaffective Disorder 
 Trigeminal Neuralgia 
 Vulvodynia 
 
MECHANISM OF ACTION 
 
The mechanism of action of carbamazepine and its derivatives is relatively 
well understood. Carbamazepine stabilizes the inactivated state of voltage-gated 
sodium channels, making fewer of these channels available to subsequently open. 
This leaves the affected cells less excitable until the drug dissociates. Carbamazepine 
is also a GABA receptor agonist, as it has also been shown to potentiate GABA 
receptors made up of alpha1, beta2, and gamma2 subunits. This mechanism may 
contribute to its efficacy in neuropathic pain and manic-depressive illness. Laboratory 
research has further demonstrated that carbamazepine is a serotonin releasing 
agent and possibly even aserotonin reuptake inhibitor. 
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PHARMACOLOGY: 
Carbamazepine is chemically related to imipramine. In addition to 
anticonvulsant properties it also has psychotropic, antidiuretic and anti neuralgic 
effects reduces polysynaptic reactions. 
Pharmacokinetics 
Pharmacokinetic data 
Bioavailability 
~100%[1] 
Protein binding 70-80%[1] 
Metabolism Hepatic—by CYP3A4, to active epoxide form  
(carbamazepine-10,11 epoxide)[1] 
Biological half-
life 
36 hours (single dose), 16-24 hours (repeated dosing)[1] 
Excretion  Urine (72%), faeces (28%)[1] 
Bioavailability Peak 
plasma 
level 
Plasma 
half-life 
Active 
metabolites 
Elimination 
variable 60-80% 
(tablets) 
6 to 12 
hours 
initially, 30 
to 50 
hours* 
later, 12 to 
17 hours* 
important** predominantly 
extrarenal 
 
*Carbamazepine induces its own metabolism, plasma half-life therefore decreases. 
**The active metabolite carbamazepine-10,11-epoxide has a half-life of 6 hours. 
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Dose 
Indication Administration Initial loading dose 
Dose Interval 
 
 
Maintenance dose 
Dose Interval 
 
 
major 
tonic-
clonic 
seizure 
oral 100-200 
mg 
12 hours 200-400 
mg 
8 to 12 
hours* 
trigeminal 
neuralgia 
oral 100 mg 12 hours 200-400 
mg 
12 hours 
 
 
 
Adverse effects 
In the US, the label for carbamazepine contains warnings concerning: 
 Effects on the body's production of red blood cells, white blood cells, and 
platelets: rarely, there are major effects of aplastic 
anaemia and agranulocytosis reported and more commonly, there are minor 
changes such as decreased white blood cell or platelet counts that do not progress 
to more serious problems 
 increased risks of suicide 
 risk of seizures, if the person stops taking the drug abruptly 
 Risks to the fetus in women who are pregnant, specifically congenital 
malformations like spina bifida, and developmental disorders. 
Common adverse effects may include drowsiness, dizziness, headaches and 
migraine, motor coordination impairment, nausea, vomiting, and/or constipation. 
Alcohol use while taking carbamazepine may lead to enhanced depression of 
the central nervous system.[1] Less common side effects may include increased risk of 
seizures in people with mixed seizure disorders, abnormal heart rhythms, blurry 
or double vision. Also, rare case reports of an auditory side effect have been made, 
whereby patients perceive sounds about a semitone lower than previously; this 
unusual side effect is usually not noticed by most people, and disappears after the 
person stops taking carbamazepine.  
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INTERACTIONS 
Carbamazepine has a potential for drug interactions; caution should be used in 
combining other medicines with it, including other antiepileptics and mood 
stabilizers.[12] Lower levels of carbamazepine are seen when administrated 
with phenobarbital, phenytoin (Dilantin), or primidone (Mysoline), which can result 
in breakthrough seizure activity. Carbamazepine, as a CYP450 inducer, may increase 
clearance of many drugs, decreasing their concentration in the blood to subtherapeutic 
levels and reducing their desired effects. Drugs that are more rapidly metabolized 
with carbamazepine include warfarin, lamotrigine, phenytoin, theophylline, and 
valproic acid Drugs that decrease the metabolism of carbamazepine or otherwise 
increase its levels include erythromycin, cimetidine, propoxyphene, and calcium 
channel blockers. Carbamazepine also increases the metabolism of the hormones 
in birth control pills and can reduce their effectiveness, potentially leading to 
unexpected pregnancies. As a drug that induces cytochrome P450 enzymes, it 
accelerates elimination of many benzodiazepines and decreases their action. 
Valproic acid and valnoctamide both inhibit microsomal epoxide hydrolase  
(MEH), the enzyme responsible for the breakdown of carbamazepine-10,11 epoxide 
into inactive metabolites. By inhibiting MEH, valproic acid and valnoctamide cause a 
build-up of the active metabolite, prolonging the effects of carbamazepine and 
delaying its excretion. 
Grapefruit juice raises the bioavailability of carbamazepine by inhibiting 
CYP3A4 enzymes in the gut wall and in the liver. 
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3.3 VALPROATE:[85-90] 
Valproate (VPA), also known valproic acid, sodium valproate, and divalproex 
sodium, is a medication primarily used to treat epilepsy and bipolar disorder and to 
prevent migraine headaches. It is useful for the prevention of seizures in those 
with absence seizures, partial seizures, and generalized seizures. It can be 
given intravenously or by mouth. Long acting formulations exist.  
BRAND NAME:-Convulex, Depakote, Epilim, Stavzor, Vilapro, Valparin 
PHARMACOLOGICAL CLASSIFICATION: Anticonvulsant 
DESCRIPTION 
Chemical IUPAC Name: 2-propylpentanoic acid 
Chemical Formula:C8H16O2 
 
STRUCTURE 
 
 
 
 
 
 
INDICATIONS: 
 Its primary use to treatment epilepsy and bipolar disorder. It is also used to 
prevent migraine headaches  
 Epilepsy 
 Psychiatric disorders 
 Migraines 
 Other 
The medication has been tested in the treatment of AIDS and cancer, owing to 
its histone deacetylase-inhibiting effects. 
Drug profile 
 
 
Department of Pharmacy Practice, K.M. College of Pharmacy  Page 55 
 
 
 
MECHANISM OF ACTION 
 
Although the mechanism of action of valproate is blockade of voltage-
dependent sodium channels and increased brain levels of gamma-aminobutyric 
acid (GABA). The GABAergic effect is also believed to contribute towards the anti-
manic properties of valproate.[38] In animals, sodium valproate raises cerebral and 
cerebellar levels of the inhibitory synaptic neurotransmitter, GABA, possibly by 
inhibiting GABA degradative enzymes, such asGABA transaminase, succinate-
semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal 
cells. It also possesses histone deacetylase-inhibiting effects. The inhibition of histone 
deacetylase, by promoting more transcriptionally active chromatin structures, likely 
presents the epigenetic mechanism for regulation of many of the neuroprotective 
effects attributed to valproic acid. Intermediate molecules mediating these effects 
include VEGF, BDNF, and GDNF.  
Valproic acid has been found to be an antagonist of the  
androgen and progesterone receptors, and hence a non-steroidal  
antiandrogen and antiprogestogen, at concentrations much lower than therapeutic 
serum levels. It was concluded that these actions are likely to be involved in the 
reproductive endocrine disturbances seen with valproic acid treatment. 
PHARMACOLOGY 
Valproate has been in clinical use for nearly 40 years for the treatment of a 
variety of neuropsychiatric illnesses, including bipolar disorder and epilepsy. Early 
reports linked its biochemical mechanism of action to alterations in gamma-
aminobutyric acid (GABA)-ergic function. The definitive mechanism(s) mediating 
the clinical efficacy of this relatively simple molecule remain obscure. Although 
valproate does not directly interact with postsynaptic GABA receptors, it does 
increase regional neuronal concentrations of GABA by both inhibiting its metabolism 
and increasing its synthesis.  
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PHARMACOKINETICS 
 
Pharmacokinetic data 
Bioavailability Rapid absorption 
Protein 
binding 
80-90%[1] 
Metabolism Hepatic—glucuronide 
conjugation 30–50%,mitochondrial 
β-oxidationover 40% 
Biological half-
life 
9–16 hours 
Excretion  Urine (30-50%) 
 
Adult: Initial dose: 10 to 15 mg/kg orally or intravenously per day as an IV 
infusion in divided doses, increased by 5 to 10 mg/kg per week if necessary 
according to clinical response 
Maintenance dose: 10 to 60 mg/kg per day in divided doses 
Maximum dose: 60 mg/kg per day 
 
Child (6 – 12 Yrs): Initial dose: 10 to 15 mg/kg orally or intravenously per day as 
an IV infusion in divided doses, increased by 5 to 10 mg/kg per week if necessary 
according to clinical response 
Maintenance dose: 10 to 60 mg/kg per day in divided doses 
Maximum dose: 60 mg/kg per day 
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CONTRAINDICATION 
Contraindications include:  
 Pregnancy 
 Pre-existing acute or chronic liver dysfunction or family history of severe liver 
inflammation (hepatitis), particularly medicine related. 
 Known hypersensitivity to valproate or any of the ingredients used in the 
preparation 
 Urea cycle disorders 
 Hepatic porphyria 
 Hepatotoxicity 
 Mitochondrial disease 
 Pancreatitis 
 Porphyria 
 
INTERACTIONS 
Valproate inhibits CYP2C9, glucuronyltransferase, and epoxide hydrolase and is 
highly protein bound and hence may interact with drugs that are substrates for any of 
these enzymes or are highly protein bound themselves.[38] It may also potentiate the 
CNS depressant effects of alcohol. It should not be given in conjunction with other 
antiepileptics due to the potential for reduced clearance of other antiepileptics 
(including carbamazepine, lamotrigine, phenytoin and phenobarbitone) and itself. It 
may also interact with: 
 Aspirin: may increase valproate concentrations. May also interfere with 
valproate's metabolism. 
 Benzodiazepines: may cause CNS depression and there are possible 
pharmacokinetic interactions. 
 Carbapenem antibiotics: reduces valproate levels, potentially leading to seizures. 
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 Cimetidine: inhibits valproate's metabolism in the liver, leading to increased 
valproate concentrations. 
 Erythromycin: inhibits valproate's metabolism in the liver, leading to increased 
valproate concentrations. 
 Ethosuximide: may increase ethosuximide concentrations and lead to toxicity. 
 Felbamate: may increase plasma concentrations of valproate. 
 Mefloquine: may increase valproate metabolism combined with the direct 
epileptogenic effects of mefloquine. 
 Oral contraceptives: may reduce plasma concentrations of valproate. 
 Primidone: may decrease pyrimidone clearance leading to toxicity. 
 Rifampin: increases the clearance of valproate, leading to decreased valproate 
concentrations 
 Warfarin: may increase warfarin concentration and prolong bleeding time. 
 Zidovudine: may increase zidovudine serum concentration and lead to toxicity. 
 
OVERDOSE AND TOXICITY 
Excessive amounts of valproic acid can result in sleepiness, tremor, stupor, 
respiratory depression, coma, metabolic acidosis, and death. In general, serum or 
plasma valproic acid concentrations are in a range of 20–100 mg/l during controlled 
therapy, but may reach 150–1500 mg/l following acute poisoning. Monitoring of the 
serum level is often accomplished using commercial immunoassay techniques, 
although some laboratories employ gas or liquid chromatography.[43] In contrast to 
other antiepileptic drugs, at present there is little favorable evidence for salivary 
therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with 
serum levels, partly due to valproate's weak acid property (pKa of 4.9).[44] 
In severe intoxication, hemoperfusion or hemofiltration can be an effective means of 
hastening elimination of the drug from the body.[46] Supportive therapy should be 
given to all patients experiencing an overdose and urine output should be 
monitored. Supplemental L-carnitine is indicated in patients having an acute 
overdose[47]. And also prophylactically  in high risk patients. Acetyl-L-
carnitine lowers hyperammonemia less markedly[49] than L-carnitine. 
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Therapeutic range of valproic acid 
Form 
Lower 
limit 
Upper 
limit 
Unit 
Total 
(including 
protein 
bound) 
50[41] 125[41] µg/mL or mg/l 
350[42] 700[42] μmol/L 
Free 
6[41] 22[41] µg/mL or mg/l 
35[42] 70[42] μmol/L 
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 Erik K St. Louis ,, William E Rosenfeld,, Thomas Bramley et al., reported 
that Antiepileptic drug (AED) monotherapy is the preferred initial management 
approach in epilepsy care, since most patients may be successfully managed with 
the first or second monotherapy utilized. This article reviews the rationale and 
evidence supporting preferential use of monotherapy when possible and 
guidelines for initiating and successfully employing AED monotherapy. 
Suggested approaches to consider when patients fail monotherapy include 
substituting a new AED monotherapy, initiating chronic maintenance of AED 
polytherapy, or pursuit of non-pharmacologic treatments such as epilepsy surgery 
or vagus nerve stimulation. Reducing AED polytherapy to monotherapy 
frequently reduces the burden of adverse effects and may also improve seizure 
control. AED monotherapy remains the optimal approach for managing most 
patients with epilepsy. 
 
 Villanueva V, Serrano-Castro PJ. et al., reported that  Zonisamide is an 
antiepileptic drug firstly approved in Europe as add-on therapy in adult patients 
with partial seizures and recently as monotherapy. It is a sulfonamide derivative 
that exerts its antiepileptic effect through different mechanisms, ion channels, 
neurotransmitters and free radicals. The efficacy of the drug was evaluated 
between 100 and 500 mg, showing a seizure reduction with respect to basal 
period between 24.7% (100 mg) and 52.5% (500 mg). The most frequent side 
effects were dizziness, fatigue, somnolence and weight loss. There is broad 
experience in conditions close to clinical practice in patients with partial epilepsy 
and different degree of refractoriness, paediatric population, monotherapy, 
generalized epilepsy and other special populations. Recently the results of a 
clinical trial in monotherapy have proved its efficacy in a no-inferiority design 
with carbamazepine. The seizure-free rate in the zonisamide group was 79.4%. 
 
 José Pimentel et al., reported that Approximately 64% of people with epilepsy 
(PWE) de novo are free of seizures with the first appropriate antiepileptic drug 
(AED) in monotherapy. The type of the first AED to use depends on the 
physician's personal choice provided that it is a first-line AED. There is a 
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tendency to prefer a substitution rather than a combination of a failed first AED 
when it was produced associated with an idiosyncratic reaction, was poorly 
tolerated at a moderate dose, or produced no improvement in seizure control. In 
contrast, there is some evidence to prefer secondary polytherapy whenever the 
PWE tolerate its first AED but with a suboptimal response. A very often used 
strategy is transitional polytherapy between two regimens of monotherapy. 
 
 Majid Ghaffarpour et al.,  reported that Seizure is a transient neurologic 
dysfunction caused by sudden abnormal firing of cerebral neurons. Epileptic 
syndrome is a complex of symptoms and signs that is characterized by not only 
the etiology but also the age at onset, seizure type, pattern of 
electroencephalography and prognosis. Treatment of the first seizures depends on 
their nature; some of them need no antiepileptic drugs (AED) therapy whereas 
the others should be treated appropriately. AEDs have long- and short-term 
adverse effects, interaction with other medications, and occupational and/or 
psychological consequences. Therefore, discontinuation of AEDs should be 
considered after a free-seizure period. Studies show that the rate of seizure 
recurrence after AEDs withdrawal is about two to three times more than those 
who continue therapy; thus, the most difficult decision facing a neurologist is 
when to start medication and when/how it should be discontinued. 
 
 Thorsten Gerstner et al., reported that Valproic acid (VPA) is considered to be a 
drug of first choice and one of the most frequently-prescribed antiepileptic drugs 
worldwide for the therapy of generalized and focal epilepsies, including special 
epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. 
Rarely, serious complications may occur in some patients, including hemorrhagic 
pancreatitis, coagulopathies, bone marrow suppression, VPA-induced 
hepatotoxicity and encephalopathy, but there is still a lack of knowledge about the 
incidence and occurrence of these special side effects. Additionally, the 
consequences for VPA therapy and indication are more or less unclear. By 
literature review and own data this review addresses some of the challenges of 
VPA therapy and its side effects, which are not unique to epilepsy in childhood.  
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 L de Jong-van den Berg et al., reported that, eight cohort studies of 2680 
pregnancies with carbamazepine monotherapy exposure, and the EUROCAT 
dataset included 98.075 registrations of malformations covering over 3.8 million 
births. Overall prevalence for a major congenital malformation after exposure to 
carbamazepine monotherapy in the first trimester. Odds ratios for malformations 
with exposure to carbamazepine among cases compared with two groups of 
controls: other non-chromosomal registrations of malformations and chromosomal 
syndromes. 
 
 Ettore Beghi et al., reported that Epilepsy is a chronic condition requiring long-
term treatment with drugs that have intrinsic limitations. Antiepileptic drugs 
(AEDs) are effective in suppressing seizures but do not alter the disease process. 
They have a suboptimal tolerability profile and can be teratogenic. Second-
generation compounds may be better tolerated but no more effective than 
traditional AEDs. The drug therapy is purely symptomatic, acute symptomatic 
seizures  may require treatment only until recovery or stabilization of the injury. 
Treatment of the first unprovoked seizure may be considered in patients with 
abnormal EEG and imaging findings and in those in whom the relapse has severe 
social, emotional and personal implications. In these cases and in patients with 
epilepsy drugs for partial seizures supported by class I regulatory trials or 
pragmatic trials are oxcarbazepine in children, carbamazepine or lamotrigine in 
adults, and lamotrigine or gabapentin in the elderly. Pragmatic trials support use 
of valproate for generalized seizures, except for women of childbearing age for 
whom the drug should be tailored to the individual patient. The lowest 
maintenance dose should be chosen, based on the efficacy and tolerability of the 
assigned drug. If the first monotherapy fails, the safety profile of a drug is 
important when opting for another monotherapy or for an add-on therapy. The 
epilepsy syndrome and the social, psychological and emotional profile of the 
patient all contribute to the individualization of treatment discontinuation after 
long-term seizure remission. 
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 BasselAbou-Khali et al., reported that Epilepsy is a common chronic disorder 
that requires long-term antiepileptic drug therapy. Approximately one half of 
patients fail the initial antiepileptic drug and about 35% are refractory to 
medical therapy, highlighting the continued need for more effective and better 
tolerated drugs. Its novel mechanism of action is modulation of synaptic 
neurotransmitter release through binding to the synaptic vesicle protein SV2A 
in the brain. Its pharmacokinetic advantages include rapid and almost 
complete absorption, minimal insignificant binding to plasma protein, absence 
of enzyme induction, absence of interactions with other drugs, and partial 
metabolism outside the liver. The availability of an intravenous preparation is 
yet another advantage. It has been demonstrated effective as adjunctive 
therapy for refractory partial-onset seizures, primary generalized tonic-clonic 
seizures, and myoclonic seizures of juvenile myoclonic epilepsy. In addition, 
it was found equivalent to controlled release carbamazepine as first-line 
therapy for partial-onset seizures, both in efficacy and tolerability. Its main 
adverse effects in randomized adjunctive trials in adults have been 
somnolence, asthenia, infection, and dizziness. In children, the behavioral 
adverse effects of hostility and nervousness were also noted. Levetiracetam is 
an important addition to the treatment of epilepsy. 
 Xiao Y, Gan L, et al., reported that the efficacy and safety of vigabatrin 
(VGB) as an add-on therapy for refractory epilepsy have been well 
established. Five studies involving a total of 734 participants were eligible for 
inclusion. We assessed only one study as good quality and the other four as 
poor quality. However, it was difficult to perform a meta-analysis by 
extracting aggregate data to synthesise the results as originally planned, 
mainly because not all studies reported the same outcomes as those chosen for 
this review. No significant differences favoured VGB or CBZ in terms of time 
to treatment withdrawal and time to achieve six-month remission after dose 
stabilisation from randomisation, but results did show a disadvantage for VGB 
on time to first seizure after randomisation. Compared with CBZ, VGB was 
associated with more occurrences of weight gain and fewer occurrences of 
skin rash and drowsiness. No differences in visual field defects and visual 
disturbances were noted. 
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 Steven Karceski, MD et al., reported that Epilepsy is the syndrome of two or 
more unprovoked seizures that occur more than 24 hours apart. Individuals who 
have had two or more unprovoked epileptic seizures are more likely to continue 
to have seizures. Seizures are disruptive in a patient's life and can cause injury. 
Epilepsy is associated with disability, adverse psychosocial outcomes, higher 
rates of psychiatric comorbidity, and an approximately threefold increased 
mortality. The management of patients with epilepsy is focused on three main 
goals: controlling seizures, avoiding or minimizing treatment side effects, and 
maintaining or restoring quality of life. The initial treatment of epilepsy is with a 
single antiseizure drug. With an ever-expanding list of available antiseizure 
drugs, and no single antiseizure drug that is clearly superior in terms of efficacy 
or tolerability, clinicians must individualize the choice of antiseizure drug for 
each patient. reported that Adverse effects of anti epileptic drugs (AEDs) can 
significantly affect the life of people with epilepsy. If polytherapy with AED has 
more adverse effects than  monotherapy. We  established a register for people 
with epilepsy. Participants were requested to complete the Liverpool Adverse 
Event Profile (LAEP) to quantify adverse effects. We also recorded type of 
epilepsy, seizure control and AED including drug doses. Five hundred and 
seventy six complete data sets were available, monotherapy (n=186), polytherapy 
(n=325) and control subjects not taking AED (n=65). The mean  LAEP scores in 
polytherapy (45.56, confidence interval (CI)=44.36-46.76) were significantly 
higher than the mean LAEP scores in monotherapy (42.29, CI=40.65-44.02) and 
the mean LAEP scores in controls (33.25, CI=31.05-35.44). Tiredness, memory 
problems and difficulty concentrating were the most common symptoms in 
patients taking AED and were consistently higher in polytherapy than in 
monotherapy. Tiredness was reported as always or sometimes being a problem in 
(polytherapy/monotherapy/controls) 82.5%/75.6%/64.6%, memory problems in 
76%/63.2%/29.2% and difficulty concentrating in 68%/63.9%/30.8%. The 
proportion of seizure-free patients was significantly lower in the polytherapy 
group (17%) than in the monotherapy group (55%). Depression rates between the 
monotherapy and polytherapy groups were similar. Drug dosages were higher in 
polytherapy, however this did not reach statistical significance. 
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Patients on polytherapy had significantly higher LAEP scores than patients on 
monotherapy. This should be carefully discussed with the patient before a second 
AED is added.  
 L M Specchio, L Tramacere, A La Neve, E Beghi  et al., reported that 
recurrence rate of epilepsy attributable to discontinuation of treatment in 
seizure free patients and to identify the risk factors for recurrence. 330 patients 
referred to an epilepsy centre who were seizure free for at least 2 years while 
on stable monotherapy were the study population. Discontinuation of 
antiepileptic drugs (AEDs) was proposed to all eligible patients or to their 
carers after discussion of the risks and benefits. Depending on whether they 
accepted or refused treatment withdrawal, the patients were stratified into two 
cohorts and followed up until seizure relapse or 31 March 1999, whichever 
came first. For each patient, records were taken of the main demographic and 
clinical variables. The sample comprised 225 patients who entered the 
discontinuation programme and 105 who decided to continue treatment. 
Twenty nine patients (28%) continuing treatment had a relapse, compared 
with 113 (50%) of those entering the withdrawal programme. For patients 
continuing treatment, the probability of remission was 95% at 6 months, 91% 
at 12 months, 82% at 24 months, 80% at 36 months, and 68% at 60 months. 
The corresponding values for patients discontinuing treatment were 88%, 
74%, 57%, 51%, and 48%. After adjusting for the principal prognostic factors, 
in patients discontinuing AEDs the risk of seizure relapse was 2.9 times that of 
patients continuing treatment. A relation was also found between relapse and 
duration of active disease, number of years of remission while on treatment, 
and abnormal psychiatric findings. 
 
 Steven C Schachter, MD et al., reported that management of patients with 
epilepsy is focused on three main goals: controlling seizures, avoiding 
treatment side effects, and maintaining or restoring quality of life. Physicians 
should assist in empowering patients with epilepsy to lead lifestyles consistent 
with their capabilities.The optimal treatment plan is derived following an 
accurate diagnosis of the patient's seizure type(s), an objective measure of the 
intensity and frequency of the seizures, awareness of medication side effects, 
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and an evaluation of disease-related psychosocial problems. A working 
knowledge of available antiseizure drugs, including their mechanisms of 
action, pharmacokinetics, drug-drug interactions, and adverse effects is 
essential. It is usually appropriate to refer the patient to a neurologist, when 
establishing a diagnosis and formulating a course of treatment. Referral to an 
epilepsy specialist may be necessary if there is doubt about the 
diagnosis and/or if the patient continues to have seizures. 
The overall approach to management of a patient with seizures is reviewed 
here. Evaluation of the patient who has had a first seizure and the 
pharmacology of specific antiseizure drugs are discussed separately. 
 Joy D Desai et al., reported that Epilepsy and cognition have a multi-tiered 
reciprocal relationship. Alteration in cognitive abilities and performance may 
occur in random with persistent seizures in a patient with epilepsy. Age at 
onset, type of seizures, frequency of seizures, types of underlying epilepsy 
syndrome, and the underlying pathological brain substrate driving epilepsy 
may all have variable and independent effects on cognition. Therapeutic 
intervention with anti-epileptic drugs (AEDs) variably modulates cognitive 
abilities in a patient with epilepsy. Pathological substrate specific effects can 
compound the potential negative effects of AEDs on cognition. In this review 
all these aspects are addressed with an analysis of relevant evidence from 
peer-reviewed publications. 
 Chaturbhuj Rathore, Ross Paterson et al., reported that Making a decision 
to withdraw antiepileptic drugs (AEDs) in patients with epilepsy in remission 
requires a careful assessment of many patient and disease related factors and 
the associated risks and benefits. Although unnecessary continuation of AEDs 
exposes the patients to unwarranted side-effects, a premature withdrawal with 
subsequent seizure recurrence may be distressing for the patient who 
otherwise considers himself as cured. Although the final decision needs to be 
individualized, there are certain guidelines which can help us in making 
evidence based decision. In this article, we intend to review the current 
evidence on this subject with an aim of providing a framework of the best 
clinical practice in this field. 
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 SitaJayalakshmi et al., reported that To determine factors associated with 
lack of response to valproic acid (VPA) in juvenile myoclonic epilepsy 
(JME).Retrospective analysis of clinical and EEG data of 201 patients with 
JME who had at least 3 years follow up was performed. Psychiatric evaluation 
was performed using ICD-10 by structured clinical interview. Patients were 
divided into two groups: VPA responders (seizure free for 2 or more years) 
and those with lack of response to VPA. Effect size for non-response and 
correlations for variables significantly different between the groups was 
performed, the findings were confirmed by ROC curves.The mean duration of 
follow up was 7.75 (range 3–12) years; 55.2% were males. Focal semiologic 
features were noted is 16%. EEG was abnormal in 67%; focal EEG 
abnormalities were noted in 32.8%. Coexisting psychiatric disorders (PDs) 
were found in 33.3%. Lack of response to VPA was noted in 19%. Diagnosis 
of PDs and focal EEG abnormalities significantly increased the risk of VPA 
non-responsiveness by 5.54 (95% CI of 2.60–11.80; p < 0.0001) and 3.01 
times respectively (95% CI of 1.40–6.47;p < 0.008). Diagnosis of PDs showed 
significant correlation (r = 0.332; p < 0.0001) and association (AUC 
0.700; p < 0.0001) with lack of response to VPA. Though focal EEG 
abnormalities increased the chances, it did not correlate with lack of response 
to VPA. 
 SonuGoel, Navpreet Singh et al., reported that Knowledge about epilepsy 
and its management is not satisfactory among school students in developing 
countries. The present study was planned to ascertain the knowledge, attitude 
and practices (KAP) of students regarding first-aid management of epilepsy 
seizures in school setting. A total of 177 students of government schools of 
Chandigarh, a city of northern India, were taken. They were administered with 
a pre-tested semi-structured questionnaire (for knowledge and attitude 
assessment) and an observational checklist after role play (for practice 
assessment) on first-aid management of epilepsy. A scoring system was 
devised to quantify the knowledge and practices of students.Seventy-one 
percent of them had either heard or read about epilepsy. Half of the students 
believed epilepsy as a hindrance to education. Ayurvedic treatment was 
preferred by more than half of the students; however, many believed that visit 
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to religious places and exorcism as ways to cure epilepsy. Nearly 74% of 
students would call a doctor as first-aid measure for seizure in a person with 
epilepsy. 
 Ettore Beghi et al., reported that Epilepsy is a chronic condition requiring 
long-term treatment with drugs that have intrinsic limitations. Antiepileptic 
drugs (AEDs) are effective in suppressing seizures but do not alter the disease 
process. They have a suboptimal tolerability profile and can be teratogenic. 
Second-generation compounds may be better tolerated but no more effective 
than traditional AEDs. In this light, as drug therapy is purely symptomatic, 
acute symptomatic seizures (i.e. seizures occurring in close temporal 
relationship with acute CNS insults) may require treatment only until recovery 
or stabilization of the injury. Treatment of the first unprovoked seizure may be 
considered in patients with abnormal EEG and imaging findings and in those 
in whom the relapse has severe social, emotional and personal implications. In 
these cases and in patients with epilepsy (i.e. repeated unprovoked seizures), 
drugs for partial seizures supported by class I regulatory trials or pragmatic 
trials are oxcarbazepine in children, carbamazepine or lamotrigine in adults, 
and lamotrigine or gabapentin in the elderly. Pragmatic trials support use of 
valproate for generalized seizures, except for women of childbearing age for 
whom the drug should be tailored to the individual patient. The lowest 
maintenance dose should be chosen, based on the efficacy and tolerability of 
the assigned drug. If the first monotherapy fails, the safety profile of a drug is 
important when opting for another monotherapy or for an add-on therapy. The 
epilepsy syndrome and the social, psychological and emotional profile of the 
patient all contribute to the individualization of treatment discontinuation after 
long-term seizure remission. 
 Joseph I Sirven, et al., reported that Patients with epilepsy whose seizures do 
not successfully respond to antiseizure drug therapy are considered to have 
drug-resistant epilepsy (DRE). This condition is also referred to as intractable, 
medically refractory, or pharmacoresistant epilepsy. As many as 20 to 40 
percent of patients with epilepsy (roughly 400,000 Americans) are likely to 
have refractory epilepsy. The annual cost for patients with epilepsy in the 
United States is estimated to be approximately 12.5 billion dollars (based on a 
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1995 survey); DRE contributes a substantive proportion of this cost. People 
with DRE have the greatest burden of epilepsy-related disabilities, further 
contributing to the scope of this problem. 
 HISAKO SHIMIZU et al., reported that Clobazam (CLB) add-on therapy 
was attempted in 183 patients with intractable complex partial seizures in 
whom conventional benzodiazepines had been successfully discontinued 
before initiation of CLB. Although complete remission was initially achieved 
in 61, tolerance developed in almost half (49.2%) within the first 3 months, 
whereas 23 out of 31 patients (74.2%) who remained seizure free for the first 3 
months continued to be so over the next 3 months. CLB add-on therapy 
proved to be significantly more effective when concurrent GTC occurred more 
often than yearly. In the current series, no frank psychotic episodes were 
elicited among the 61 patients who achieved complete suppression of long-
standing complex partial seizures, which was in agreement with previous 
studies. From these results, we believe that CLB is an effective, safe, and 
inexpensive medication for add-on therapy it is difficult to treat focal 
epilepsies, especially without concurrent use of conventional benzodiazepine 
compounds. 
 Peter R. Camfield* and Carol S, reported et al., that in the first 5 years of 
epilepsy treatment as an average of at least one seizure every 2 months. For 
the longer term, we define intractable as at least one seizure per year. 
Population studies from Chicago, IL, U.S.A., Finland, and Nova Scotia, 
Canada indicate that with long follow-up, many children with intractable 
epilepsy eventually have remission of their seizure disorder. Epilepsy is no 
longer intractable when the seizures stop completely. How often does a new 
antiepileptic drug (AED) render a child seizure-free when one or more AEDs 
have failed? Literature on adults with epilepsy suggests that few with chronic 
epilepsy who have not achieved seizure control with several AEDs will 
achieve complete seizure control with additional AEDs. The Nova Scotia 
study suggests that if a child's seizure fails to be controlled with a first AED, 
there is an increased risk of intractable epilepsy. Nonetheless, the chance of 
eventual, complete remission of epilepsy (seizure-free without AED 
treatment) is approximately 40%. We conclude that intractability should not 
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be considered until there has been failure of at least three first-line AEDs. 
Intractable epilepsy is rare. Careful definition of the characteristics of 
children with intractable epilepsy who do respond completely to new AEDs 
will likely provide the only rational approach to treatment of children with 
three drug failures. Collaboration by multiple epilepsy centers will be 
required to gain this information. 
 U K Misra,J Kalita,   C Rathore et al., reported that Cross reactivity 
between phenytoin, carbamazepine, and oxcarbazepine is reported. An 8 year 
old boy with partial seizures developed maculopapular rashes with itching on 
day 15 of carbamazepine therapy. After stopping carbamazepine, phenytoin 
100 mg daily was prescribed two days later. On the 12th day of phenytoin 
therapy he developed cervical and axillary lymphadenopathy with fever. 
Lymph nodes revealed reactive hyperplasia. Oxcarbazepine 75 mg twice 
daily also resulted in oral and mucosa ulceration. The seizures were 
controlled without any side effects with sodium valproate 200 mg three times 
a day and gabapentin 300 mg twice a day. Due to the cross reactivity of 
aromatic anticonvulsants (phenytoin, carbamazepine, and oxcarbazepine), 
valproate or newer anticonvulsants should be used if a patient has sensitivity 
to these drugs. 
Phenytoin, phenobarbitone, and carbamazepine are first line 
antiepileptic drugs. Despite the availability of newer antiepileptic drugs, these 
first line drugs are commonly used because of their efficacy and low cost. 
These drugs have the limitation of a high toxicity, which involves the skin, 
liver, brain, kidney, and the gastrointestinal and haemopoetic systems, and 
these drugs result in both dose related toxicity and hypersensitivity reactions. 
The clinical spectrum of first line antiepileptic drugs is quite wide, ranging 
from a subtle skin rash to life threatening systemic toxicity and from benign 
lymphadenopathy to an association with malignant lymphoma.1,2 An overlap 
between phenytoin and carbamazepine toxicity has also been reported,3 which 
is not commonly appreciated by treating physicians. We recently managed a 
patient who had a skin reaction after carbamazepine and oxcarbazepine and 
lymphadenopathy after phenytoin treatment. We report this patient and 
highlight the problem of cross reactivity among first line antiepileptic drugs. 
Aim and objectives 
 
 
Department of Pharmacy Practice, K.M. College of Pharmacy  Page 71 
 
 
 
AIM AND OBJECTIVES 
 
AIM: 
 To study the comparison between the remission occurrence while giving 
therapies (Mono/Add on) including AED’s in the treatment of epileptic seizures & 
evaluate the patients access to medical care who were under the treatment of General 
Medicine Department of New Life Society, Bethesda  Hospital, Tuticorin. 
 
OBJECTIVES 
 
 
 To identify the various precipitating factors & emotional symptoms,  to assess 
the side effects caused by the drugs.  
 To know about the choice of therapies (Mono/Add on) including AED’s in 
treatment of Epileptic seizures. 
  To evaluate the respondents access to medical care belongs to regional and 
urban population. 
 To study the epidemiological factors and etiological factors of epilepsy. 
 To develop guidelines for the first aid treatment of epilepsy. 
 To develop guidelines for the management of epilepsy and seizures. 
 To give effective patient counselling for epilepsy patient. 
 To study the management of the adverse drug reaction and side effects. 
 To find out the remission occurrence in the mono and add on therapy in 
epilepsy. 
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NEED FOR THE STUDY 
 
 While the evaluation and treatment of patient with seizures (or) epilepsy is 
often challenging. Modern Therapy provides many patients with seizure control. After 
a first seizure evaluation should focus on excluding an underlying neurologic or 
medical condition assessing the relative risk of seizure reoccurrence & determining 
whether treatment is indicated. Successful management of patient with recurrent 
seizure begins with the establishment of accurate diagnosis of epilepsy syndrome 
followed by treatment using an appropriate medication in a manner to optimize the 
efficacy. The goal of AED’s therapy is to completely control seizures with producing 
an acceptable medication side effects.   
 
 Patients who do not achieve complete seizure control should refer to an 
epilepsy specialist since new medication and surgical treatment offers patients 
unprecedented options in seizure control Topics for information provision and 
counseling newly diagnosed epileptic patients and principle of treatment in chronic 
epilepsy help in designing steps to improve the safety of drug use in the hospital 
working set up. Better health care practice could be ensured by applying this 
knowledge to individual patients. 
 
 Present study was undertaken to understand the treatment outcome of 
AED’s observed in neurology unit of a teaching hospital. With regarding to 
demography of patients choice of prescribed AED’s usual  dosing regimens and faster 
routine incremental and decremented rates, Management of seizure and identify 
precipitating factors of epilepsy. The holy grail of epilepsy an AED that is 100% 
effective but has no adverse effects or drug interactions.  
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METHODOLOGY 
 
Study site: General Medicine department of New Life Society, Bethesda Hospital,  
                  Tuticorin. 
Study Duration: 6 Month (August 2015 to January 2016) 
Study Design:Monotherapy & Add on therapy with cohort study 
Dosage 
Carbamazepine (Tegritol): 200mg/day, twice a day  
Phenytoin Sodium (Eptoin): 100mg/day, twice a day 
Valproate (Depakine): 200mg/day, twicw a day 
Phase 1: 
 Discussion about the use of various types of epilepsy and seizures of different 
hospitals. 
 Enquiring of the relevance of this study with Dr.J.Selvakumar,M.D., 
Consultant in General Medicine department.  
Phase 2 
 Designing of the methodology of the study was done. 
 Case report forms were prepared and the different rating scales of epilepsy were 
collected. 
Phase 3: 
 50 Patient having epilepsy and seizure during the study period 6 Month (August 2015 
to January 2016) were independently evaluated by the epilepsy and seizures who initially did 
the clinical interview and arrived at a diagnosis using inclusion criteria & exclusion criteria. 
Inclusion Criteria: 
 Newly diagnosed & established patients in Neurology department for management of 
epileptic seizures. 
 Age more than 14 years. 

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Exclusion Criteria: 
 Patient referred to Neurology department for evaluation. 
 Patients visiting on outpatient basis. 

Phase: 4   
 After AED selection has been made, starting with a low dose and gradually titrating to a 
moderate and presumably effective dose is a reasonable strategy, since titration to higher 
doses.  
 A more rapid titration may be necessary in selected patients who have had multiple recent 
seizures. Maximizing the dose is only recommended in patients who do not respond to 
moderate doses.  
 At each patient visit, it is necessary to conduct a detailed assessment of AED therapy, 
including adverse effects and compliance.  
 Utilizing a quantitative survey of patient’s perceived adverse effects such as the adverse 
events profile (AEP) has been prepared alter antiepileptic drug therapies to for improving 
quality of life.  
 
Phase 5 
Measurement of efficacy and safety 
 A clinicians rating of “much improved” or “very much improved” on the clinical 
global impression of improvement. 
Phase 6: 
 Interpretations of the results are done and the efficiency and safety of each drug group 
is determined. 
 Conclusions was made. 
Ethical consideration: 
 Before conducting the study an approval from the Dean of the Hospital were taken 
and an official permission were taken from the Director of the selected setting to 
conduct the study. An approval to participate in the study was taken from mothers 
during interview ensuring confidentiality and their right's to accept or refuse 
participation. 
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Method of collection of data:- 
 Patient Interview. 
 Hamilton rating scale for epilepsy. 
 Clinical global impression scale. 
 Patient case notes. 
 Treatment chart. 
The patients satisfying the inclusion criteria were assessed for the severity of the illness 
using. 
1. Clinical global impression scale (CGI). 
 
CLINICAL GLOBAL IMPRESSION SCALE (CGI-SCALE) 
Patient Name: -------------- 
1. SEVERITY OF ILLNESS 
Considering the total clinical experience with this particular population, how mentally 
ill is the patient at this time? 
0. = Not assessed                                      3. =Mildly ill 
1. = Normal, not at all     4. =Moderately ill 
2. = Border line ill     5. =Markedly ill 
6.   = Severely ill      7. =Among the most extremely ill. 
 
2. GLOBAL IMPROVEMENT 
Rate total improvement whether are not in your judgement, it is a due to entirely to 
drug treatment. 
Compared to the patient’s condition when first assessed, how much change has 
occurred? 
 
0. = Not assessed     4. =Minimally worse 
1. =Very much improved    5. =Much worse 
2. =Very improved     6.  =Very much worse 
3. =Minimally improved    7. =No change 
A suitable case report form was prepared which was used for the storage of data. 
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The data’s collected were, 
 The patient details 
 The stage of the disease and duration of episode 
 Concomitant diseases 
 The signs and symptoms during examination  
 CGI scores 
 Details of medication  
 Significant adverse drug reactions  
 The data were collected for each visit of the patients 
STATISTICAL ANALYSIS 
Statistical Tools: 
The information collected regarding all the selected cases were recorded in a Master 
Chart. Data analysis was done with the help of Graph Pad instate (GPI V3.0). Using these 
software mean, Standard Deviation (SD), Standard Error Mean (SEM) and p values were 
calculated. A ‘p’ value less than 0.05 is taken to denote significant relationship. Data’s were 
presented in mean, SD and percentage as applicable.  
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OBSERVATION AND RESULTS 
PATIENT DEMOGRAPHIC CHARACTERISTICS 
Table: 1 GENDER DISTRIBUTION 
 
      Mean value = 25                  Standard Value (SD) = 4.243  
P value is 0.0760 considered not quite significant 
t value 3.727 with 2 degrees of freedom 
 From the above table, Out of the 50 patients 22 (44%) were males and 28 (56%) were 
females. This shows that female patients were mostly affected by disorders than male 
patients. 
FIGURE.1 GENDER DISTRIBUTION 
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S.no Gender Number of patients Percentage 
1 Male 22 44% 
2 Female 28 56% 
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Table: 2 CLASSIFICATIONS OF PATIENTS BY AGE GROUP 
 
S.no Age group(years) Number of Patients Percentage  
1 15-25 11 22 % 
2 26-35 13 26 % 
3 36-45 15 30 % 
4 46-55 8 16 % 
5 56-65 3 06 % 
 
     Mean value = 10          SD value = 4.690 
P value is 0.00089 considered very significant      
 t = 4.767 with 4 degrees of freedom 
 
FIGURE.2 CLASSIFICATION OF PATIENTS BY AGE GROUP 
 
 Out of 50 patients11 patients were under the age group of 15 to 25, 13 patients 
were under the age group of 26 to 35, 15 patients were under the age group of 36 to 
45, 8 patients were under the age group of 46 to 55, 3 patients were under the age 
group of  56 to 65. 
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TABLE: 3 CLASSIFICATION OF PATIENT’S ILLNESS 
Age 
Group 
Severity of illness Total 
no of 
patients 
Percentage 
Borderline 
ill 
mildly 
ill 
Moderately 
ill 
Markedly 
ill 
15-25 2 2 4 2 10 20% 
26-35 4 8 0 2 14 28% 
36-45 4 4 6 2 16 32% 
46-55 2 4 0 0 6 12% 
56-65 2 2 0 0 4 8% 
Mean value: 2.800,                                                                       SD Value:1.095 
P Value is 0.0046 considered very significant 
t value 5.715 with 4 degrees   of  freedom 
FIGUER-3 CLASSIFICATION OF PATIENT’S ILLNESS 
 
  Out of 50 patients 20% patients were under the age of 15-25, 28% 
patients were under the age group of 26-35, 32% patients were under the age of 36-
45, 12% patients were under the age group of 46-55 and 8% patients were under the 
age group of   56-65. This shows that the maximum no of patients were under the age 
group of  36-45 were affected  by moderate illness. 
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TABLE: 4 MARITAL STATUS 
MARITAL 
STATUS 
NO. OF 
PATIENTS 
MALE FEMALE PERCENTAGE 
MARRIED 39 14 25 78% 
UNMARRIED 11 8 3 22% 
      Mean value:25                                    SD value:19.799 
P Value is 0.3250 considered not significant 
t value 1.786 with 1 degree of freedom 
 In this study out of 50 patients 39 were married and 11 were unmarried 
so we came to know married persons were affected by epilepsy and females were 
mostly affected by epilepsy and seizures. 
 
FIGURE 4 MARITAL STATUS 
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TABLE: 5 OCCUPATIONAL STATUS 
OCCUPATION NO.OF PATIENTS PERCENTAGE 
HOUSE WIFE                    9  18% 
BUSINESS                   11                 22%  
PRIVATE 
EMPLOYEES 
      06                 12% 
STUDENT   05       10% 
AGRICULTURE                   07                  14% 
UNEMPLOYED                   12                 24% 
          Mean value = 8.33                                        SD = 2.805 
P value is 0.0008 considered very significant  
t value   7.278   with 5 degrees of freedom  
FIGURE 5 CLASSIFICATIONS OF PATIENTS BY THEIR OCCUPATION 
 
Out of the 50patients, 9 patients were house wife, 11 patients were business 
man 6 patients were private employees 5 patients is student, 7 patients were 
agriculturist and 12 patients were unemployed. This data shows that the maximum 
number of epilepsy patients were unemployed. 
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TABLE: 6  ETIOLOGICAL FACTORS 
FACTORS NO. OF PATIENTS PERCENTAGE 
PHYSICAL ILLNESS 16 32% 
JOB PROBLEM 05 10% 
LOSS OF CLOSE FAMILY 
MEMBERS 
05 10% 
FINANCIAL PROBLEMS 07 14% 
FAMILY PROBLEMS 06 12% 
MARITAL CONFLICTS 07 14% 
ACADEMIC PROBLEM 01 02% 
NO SPECIFIC REASON 03 06% 
        Mean value = 6.25                                      SD = 4.432 
P value is 0.0053 considered very significant  
t value   3.989   with 7 degrees of freedom  
FIGURE 6 ETIOLOGICAL FACTORS 
 
 Out of the 50 patients, 16 patients had physical illness as the etiological factor 
for epilepsy 5 patients had job problems, 5 patients had a problem of loss of close 
family members, 7 patients had financial problems, 6 patients had family problems, 7 
patients had marital conflict, 1 patient had academic problem and 3 patients had no 
specific reasons. 
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TABLE: 7 SOCIAL HABITS OF PATIENT 
S.NO SOCIAL HABITS NUMBER OF 
PATIENTS 
Percentage 
1 Smoker  4 8% 
2 Smoker & Alcoholic 3 6% 
3 Non Smoker & 
alcoholic 
43 86% 
 
            Mean value =18.33                                  SD = 21.572 
P value is 0.2789 considered not significant  
t value 1.472   with 2 degrees of freedom 
Out of 50 patients, 4 patients are having smoking habits and 3 patients are alcoholic. 
43 patients doesn’t have habit of smoking and alcoholism. 
 
FIGURE NO:7 SOCIAL HABITS OF PATIENT 
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TABLE: 8 FAMILY HISTORY 
 
CATEGORY NO. OF PATIENTS PERCENTAGE 
FAMILY HISTORY 6 12% 
NO FAMILY 
HISTORY 
44 88% 
 
      Mean value = 25                                                   SD = 26.870 
P value is 0.4137 considered not significant  
t value  1.316   with 1 degree of freedom 
 
FIGURE: 8 FAMILY HISTORY 
 
Out of 50 patients 6 patients had a close relative with epilepsy whereas 44 patients 
had no Family history. 
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Table 9. ANTI EPILEPTIC DRUG PRESCRIPTION PATTERN 
(MONO-THERAPY) 
 
S.no Prescribed AED's No.of patients % Prescription 
1 CARBAMAZEPINE 12 24% 
2 PHENYTOIN SODIUM 14 28% 
3 VALPROATE 08 16% 
 Mean value = 11.33                                                             SD = 3.055 
P value is 0.0453 considered significant  
t value   2.874   with 4 degrees of freedom 
FIGURE 9. ANTI EPILEPTIC DRUG PRESCRIPTION PATTERN               
(MONO-THERAPY) 
 
 
 
 Out of 34 patients are treatment in mono therapy. 12 (24%) patient’s 
prescription pattern in carbamazepine, 14 (28%) patient’s prescription pattern in 
phenytoin sodium, 8 (16%) patients in prescription pattern in valproate. 
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TABLE 10. ANTI EPILEPTIC DRUG PRESCRIPTION PATTERN                      
(ADD ON-THERAPY) 
 
S.NO Prescribed AED's No. of patients %of prescription 
1 C+P 07 14% 
2 P+V 05 10% 
3 V+C 04 08% 
         Mean value = 5.33                                             SD = 1.528 
P value is 0.0263  considered  significant  
t value   6.047   with 4 degrees of freedom 
FIGURE 10. ANTI EPILEPTIC DRUG PRESCRIPTION PATTERN                   
(ADD ON-THERAPY) 
 
Out of 16 patients are treatment in add on therapy. 7 (14%) patients 
prescription pattern in C+P, 5(10%)  patients prescription pattern in P+V. 4(8%) 
patients prescription pattern in V+C. 
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Table 11. RECURRENCE OF SEIZURE IN THE STUDY 
POPULATION 
 
  Mean value = 18.5                                                     SD = 11.475 
P value is 0.0484 considered  significant  
t value 3.225  with 3 degrees  of freedom 
FIGURE11. RECURRENCE OF SEIZURE IN THE STUDY POPULATION 
 
 
Recurrence of seizure after first treatment in 0 weeks 34(68%) patients, 24 weeks 
20(40%), patients, 48 weeks 12(24%) patients, 72 weeks 8(16%) patients. 
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TABLE 12. OUTCOME OF EMOTIONAL SYMPTOMS 
S.No  Emotional symptoms  
No.of 
patients  
%of Emotional 
symptoms 
1  Anxiety  15  30% 
2  Depression  09  18% 
3  Mood disturbance  06  12% 
4  Migraine  10  20% 
5  Behavioral disorder  04  08% 
6  None  06  12% 
 
            Mean value = 8.33                                              SD = 3.933 
P value is 0.0035 considered very significant  
t value   5.190   with 5 degrees of freedom 
FIGURE 12 OUTCOME OF EMOTIONAL SYMPTOMS 
 
Out of 50 patients outcome emotional symptoms in, anxiety patients 15(30%) 
depression patients 9(18%), mood disturbance patients 6(12%), migraine  patients 
10(20%), behavior disorder patients 4(8%), None patients 6(12%) were occur. 
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TABLE: 13 KNOWLEDGE OF FIRST AID IN THE STUDY 
POPULATION 
 
 
 
 Mean value = 25                                           SD = 14.142 
P value is 0.2422 considered not significant  
t value  2.500   with 1 degree of freedom 
 
FIGURE: 13 KNOWLEDGE OF FIRST AID IN THE STUDY POPULATION 
 
 
 
 
Out of 50 patient’s knowledge of first aid in 15(30%) patients, NO knowledge of first 
aid in 35(70%) patients. 
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TABLE: 14 ASSESSMENT OF CLINICAL RESPONSE USING 
THE CLINICAL GLOPAL IMPRESSION SCALE (CGI SCALE) 
 
Drug therapy Global 
Improvement 
No of Patient Percentage 
 
Mono therapy 
Minimally 
Improved 
5 10% 
Much Improved 23 46% 
Very Much 
Improved 
1 2% 
No Change 5 10% 
 
Add on therapy 
Minimally 
Improved 
1 2% 
Much Improved 9 18% 
Very Much 
Improved 
1 2% 
No Change 5 10% 
 
  Mean value: 2.800                                                                           SD value:1.095 
 
P value is 0.0046 considered very significant 
t value is 5.715 with 4 degrees of freedom 
 
  From the above table with mono therapy 46% of patients were much 
improved, 10% of patients were minimally Improved. 2% of patients produce very 
much Improved condition with add on therapy much improved and of patients were 
18% compared to other responses. 
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FIGURE 14 ASSESSMENT OF CLINICAL RESPONSE USING THE 
CLINICAL GLOPAL IMPRESSION SCALE (CGI SCALE) 
 
 
 
CGI scale is used in epilepsy treatment. In Mono therapy treatment 34 patients are 
involved. 5 patients are minimally improved, 23 patients are much improved, 1 
patient is very much improved, 5patients showed no change. 
     Add on therapy treatment in 16 patients. 1 patient in minimally improved stage, 9 
patients are much improved, 1 patient in very much improved, 5 patients shows no 
change. 
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TABLE: 15 REMISSIONS OCCURRED DURING TREATMENT 
 
S.No Remission during 
therapy 
No.of.Patients % of Remission 
  + - + - 
1 Mono therapy 25 9 50% 18% 
2 Add- on therapy 10 6 20% 12% 
 
             Mean value = 8.5                                                              SD = 0.7071  
P value is 0.0374 considered  significant  
t value   17.000   with 1 degrees of freedom 
Out of 50 patients remission occurred in mono therapy 25(50%) + ve, 9(18%) –ve, 
patients Add on therapy 10 (20%) +ve, 6(12%) –ve patients. 
FIGURE: 15 REMISSION OCCURRED DURING TREATMENT 
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DISCUSSION 
 The concept of treatment of seizures with modern therapy is relatively new in 
India. In developing countries the neurology treatment is become burden to the 
people. Due to rapid growth in population, general lack of education, health 
awareness and socio economic status. There is no racial geographical or social class 
boundaries of seizures occurs in both genders, at all ages, especially in childhood, 
adolescents and increasingly in ageing population, while the condition can have 
profound physical and psychosocial consequences, appropriate treatment can  prevent 
long term damage. While there is no cure for the condition there are various ways-
people can control or manage symptoms to improve their quality of life particularly if 
the condition is identified and managed early. 
 In this study a total of 50 patients comprising 22 (44%) males & 28 (56%) 
female were selected from the department of general medicine, New Life Society, 
Bethesda Hospital, Tuticorin.  In the present study the percentage privilege of female 
patients is high when compared with male patients in the study population. For the 
treatment  of epilepsy in women monotherapy is recommended during  the 
reproductive years to reduce the risk  teratogenicity seen with poly pharmacy. 
  
        On the classification of patients according to the age group the maximum 
number patients according to the age group the maximum number of patients were 
under the age group of 36-45 (30%).Other age group in 15-25 (22%), 26-35 (26%), 
46-55(16%), 56-65(6%).This results indicates that most of the epilepsy patients were 
under the age group of  26-45.   
        Classification of Illness table shows, mildly ill patients are mostly in 20 (40%) 
moderately ill patients 10, markedly ill patients 6, Border line ill patient 14. This 
result showed  severity of  illness more in 36-45 years (32%). 
       The number of married patients were 39(78%) compared to unmarried patients 
11(22%) . 
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   The higher number of epilepsy patients were unemployed 12(24%) because they are 
not able to work. House wife 9(18%), Business man 11(22 %), Private employees 6 
(12%), Student 5(10%), Agricultural 7(14%)  
       When comparing the etiological factors for epilepsy higher number of patients 
16(32%) had a physical illness as the cause. The other causes responsible for the 
incidence of epilepsy were job problem 5(10%), loss of close family members 
5(10%), financial problems 7(14%) family problems 6(12%) marital conflicts 7(14%), 
academic problem 1(2%).There is no specific reason for 3(6%)  
        In social habits smoker are 4(8%) of patient and smoker and alcoholic are 3(6%) 
and 43(86%) of patients were non smoker and  non alcoholic. 
        12% of patients had a family history of epilepsy. 88% of patients had a no family 
history. 
 Generally most of the seizures effectively treated with Anti-epileptics and 
Anticonvulsants. These are prescribed according to the patient clinical response. At 
present according to the diagnosis following drugs were given Carbamazepine (24%), 
Phenytoin sodium (28%), Valproate (16%), to the patients as monotherapy treatment 
based upon their seizure frequency.  
 AED didn’t show effective result then choose Add on therapy for getting 
effective results. In this therapy second drug is added to low doses and  then gradually 
first AED dose was decreased and second drug is then further optimized based on 
seizure response. Among the different types of AED’s combinations in the present 
study C+P (14%), P+V (10%), V+C (8%) were given to the patients as Add on 
therapy in the study population. 
 Although few studies were conducted specifically in patients with seizures who 
are using AED’s in high doses, they found most common side effects were occurred. 
So most of the Anticonvulsant drugs were needed to be introduced slowly to 
minimize side effects such as Nausea, Vomiting etc., after first treatment of seizure 
the recurrence should be effectively controlled by using successful management. In 
this study the percentage of recurrence of seizure is gradually decreased in range of 
40%, 24% and 16% for every 6 months. 
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 In this study we found that remission (68%) had achieved most often due to 
mono therapy because mono therapy is the goal whenever possible. The possibility of 
using Add on therapy is rare in the study population because most of the patients got 
remission by mono therapy itself. 
         Out come of emotional symptoms mostly in anxiety 15 (30%) and depression in 
9 (18%), mood disturbance 6(12%), migraine 10(20%), behavioral disorder 4(8%), 
none 6(12%).  
 All patients were counselled with the help of quality care check list form, during 
the counseling when came to know about their awareness regarding self-care and first 
aid. Results in 35(70%) population don’t have proper knowledge  of epilepsy and 
some have little bit of knowledge 15(30%),  
      CGI scale is used in epilepsy treatment. Monotherapy treatment 23(46%) patients 
are much improved, 5(10%) patients are minimally improved, 1(2%) patient very 
much improved, 5(10%) patients showed no change. Add on therapy treatment 
9(18%) patients are much improved, 1(2%) patient minimally improved, 1(2%) 
patient very much improved, No change was observed  in 5(10%)  
      The remission occurred during treatment  are Mono therapy in number of patients  
+ (25) -(9).The percentage of remission in mono therapy + (50%),-(18%).The 
remission occurred during treatment with Add - on therapy in number of patients 
+(10),-(6).The percentage of remission in Add-on therapy +(20%),-(12%).  
     Educating the patient about epilepsy, AED compliance, seizure first-aid is 
important for ensuring successful therapy. AED selection is determined by seizure 
type, patient medical history, and concurrent medications. 
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CONCLUSION 
 
 The incidence of epilepsy is 24-53% of population in developing countries. 
However over 30% of people with epilepsy or seizure don’t have seizure control even 
with the best available medications. 
 AED’s therapy is the main stay of treatment for most patients with epilepsy. 
The overall goal is to completely prevent seizures without causing any untoward side 
effects, preferably with single medication and a dosing schedule that is easy for the 
patient to follow. Because the response to any anti epileptic drug is unpredictable so 
patient should be carefully educated about approach to therapy.  
 Most of the generalized seizure patient take monotherapy. In this adverse 
effect occurrence was less compared to add on therapy. Add –on-therapy taken long 
term treatment with more side effect. But in monotherapy duration of treatment short 
with less side effect .The vast majority of patients had remission by mono therapy 
treatment .Co operation between the patient, physician and pharmacist results best 
possible outcome. 
There is a long tradition of treating epilepsy patients with two or more AEDs. 
However, in the past decade monotherapy has emerged as the ultimate treatment 
strategy for both newly-diagnosed and long-term patients because of fewer side 
effects, better compliance, less teratogencity and lower cost. 
 
Reducing AED polytherapy to monotherapy frequently reduces the burden of 
adverse effects and may also improve seizure control. AED monotherapy remains the 
optimal approach for managing most patients with epilepsy. 
 
 Tips regarding first aid for making the people physically and mentally ready to 
help the people who were getting sudden occurrence of seizures. By this way we can 
get tremendous change in reducing Sudden Unexpected Deaths in Epilepsy (SUDEP) 
and we were succeeded in achieving our main goal to maximize the quality of the life 
by minimizing the seizures activity.  
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PATIENT PROFORMA 
 
PATIENT DETAILS 
   
PATIENTS HOSPITAL DETAILS: 
HOSPITAL OP/IP NO: 
ADDRESS: 
 
NAME  
C/O  
DOOR NO  
STREET NAME  
AREA  
LANDMARK  
CITY/ VILLAGE   
PHONE NUMBER  
MOBILE NUMBER  
 
 
DEMOGRAPHICS: 
 
DATE OF BIRTH:    AGE IN YEARS:  
 
SEX    :           Male 
 
               Female 
PLACE   : 
 
OCCUPATION   : 
 
INCOME    :  Above 20000 per month 
11000 to 20000 per month 
      5000 to 10000 per month 
      Below 5000 
 
EDUCATION   :  Did not Complete High School / Secondary  
School  
Appendix 
 
Department of Pharmacy Practice, K.M. College of pharmacy   
 
Completed High School / Secondary  
School  
Completed College (Bachelors) 
Completed Post Graduate Education 
(Masters/Phd.,) 
MARRIAGE DETAILS :  Married Unmarried    Separated 
  
SOCIAL BEHAVIOR: 
  
Does the subject use tobacco? :        Current Use    Past Use  Never Use 
 
If Current Use for Long? :    Years  Month 
 
Does the subject use Alcohol?      Yes         No 
 
If Current Use for Long? :    Years  Month 
 
Does the subject use Food? :     Vegetarian        Non-Vegetarian 
 
 
 
 
HISTORY OF INDEX ILLNESS EPILEPTIC SEIZURES 
 
FAMILY HISTORY 
KNOWLEDGE OF FIRST AID :     Yes  
          No 
ANY OF YOUR FAMILY  
MEMBERS HAD PREVIOUS  
HISTORY OF EPILEPSY?  :      Yes  No 
If, Yes Related Mention the       
TYPE OF EPILEPSY   : 
 
ETIOLOGICAL FACTOR  :     Environmental  
    Physical Illness 
    Drug Therapy 
    No Specific Factor 
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OUT COME OF EMOTIONAL 
SYMPTOMS     
  
1. ANXIETY   :  
 
2. DEPRESSION  : 
 
3. MOOD DISTURBANCE : 
 
4. MIGRAIN   : 
 
5. BEHAVIOUR DISORDER : 
 
6. NONE    : 
 
MADICATION HISTORY 
 
A. PREVIOUS TREATMENT : 
  
DATE OF ONSET MONTH/YEAR DURATION MONTH/YEARS 
  
  
  
 
B. ONSET OF CURRENT ILLNESS…………………………………… MONTH 
AND YEAR  
 
C. PRESENT TREATMENT :  
 
MEDICATION DOSE START DATE STOP DATE RESPONSE TO 
TREATMENT 
     
     
     
 
 
*Please enter one of the following.: very good, Good, Moderate, Poor, Very poor, 
Unknown. 
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VITAL SIGNS: 
 
ORAL BODY TEMPERATURE:                                  oC               OF 
     
WEIGHT:                                                                                       Kg              Lbs 
 
HEIGHT:                                                                                        Cm            Inches 
 
RESPIRATORY FREQUENCY:  
 
BLOOD PRESSURE: 
 
SITTING/ 
STANDING 
TIME VITAL 
SIGNS TAKEN 
(24- Hour) 
BLOOD 
PRESSURE 
(mmHg) 
HEART 
RATE(bpm) 
After 5 Minutes    
After 2 Minutes    
 
Are any vital signs abnormal and clinically significant? Yes…..  No……… 
 
CONCOMITANT MEDICATION 
 
Is the subject currently taking any medication          Yes             No 
 
ADVERSE EFFECTS 
 
Is here any Adverse effect is arise please enter of the following (2nd visit)  
Nausea     
 
Vomiting 
 
Increased Sweating 
 
Constipation 
 
Head Ache 
 
Dizziness 
 
Others 
 
RECURRENCE OF SEIZURE 
IN STUDY POPULATION  :    0 WEEKS  
      24 WEEKS 
     48 WEEKS 
72 WEEKS 
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PRESCRIPTION PATTERN   : MONO THERAPY 
ADD ON THERAPY 
 
 
REMISSION OCCURRED  
DURING TREATMENT              : MONO THERAPY 
ADD ON THERAPY 
 
 
 
 
 
TIME TAKEN FOR REMISSION :  
 
 
 
 
; 
EPILEPSY FIRST AID BOOKLET IN TAMIL 
 
fhf;if typg;G Nehahspapd; mwpT Nfs;tpj;jhs; 
1. typg;G Neha; vd;gJ? 
m) kdNeha; M) %is euk;gpay; Neha; 
,) rhgj;jpdhy; tUtJ  <) guk;giu Neha; 
2. typg;G Neha; te;jhy; nra;af;$ba Kjy; cjtp? 
m) ifapy; ,Uk;G Nghd;w MAjq;fis nfhLf;f Ntz;Lk; 
M) XU Gwkhf gLf;f itj;J fhw;Nwhl;lkhf itf;f Ntz;Lk; 
,) rj;jk; Nghl;L FYf;fp vOg;g Ntz;Lk; 
<) thapy; czT my;yJ [P]; nfhLf;f Ntz;Lk; 
3. typg;G Neha; vg;gb guTfpwJ?  
m) Nehahsp ,UKk; NghJ   M) Nehahspia kw;wth;fs; njhLtjpdhy;    
,) xNu tPl;by; ,Ug;gjhy;    <) vJTk; ,y;iy 
4. fPo;fz;ltw;wpy; vJ rupahdJ? 
m) typg;G te;jth;fis gy te;jkhf gpbj;J fl;Lg;gLj;j Ntz;Lk; 
M) typg;G te;jtupd; ehf;if gpbj;J nfhs;s Ntz;Lk; 
,) typg;G te;jtupd; if> fhy;fis gpbj;Jf; nfhs;s Ntz;Lk; 
<) typg;G te;jtiu Rw;wp $l;lk; Nghlhky; xU Gwk; rha;j;J gLf;f itj;J 
mikjpahf tplTk;. 
5. fPo;fz;ltw;wpy; vJ rup? typg;G Neha; ahiu jhf;FfpwJ?  
m) Mz;fis kl;Lk; ghjpf;fpwJ 
M) gbf;fhjtu;fis kl;Lk; ghjpf;fpwJ 
,) Viofis kl;Lk; ghjpf;fpwJ 
<) Mz;> ngz; kw;Wk; gbj;jtu; gbf;fhjtu;fs;> Vio> gzf;fhuu; vy;NyhiuAk; 
ghjpf;fpwJ. 
6. typg;G Neha; gw;wp cq;fs; fUj;J? 
m) %isapy; kpf mjpfkhd kw;Wk; xOq;fw;w kpd;rhu rf;jp ntspg;gLtjhy; 
Vw;gLfpwJ. 
M) gpy;yp #dpaj;jhy; Vw;gLfpwJ  
,) Kd;Ndhh;fs; ghtj;jpdhy; cz;lhfpwJ 
<) njupahJ 
; 
 
 
 
7. typg;G Neha; te;jth;f;F FLk;gj;jhh; nra;a Ntz;baJ? 
m) KO Mjuthf ,Uf;f Ntz;Lk;  
M) jdpahf xJf;fp tpl Ntz;Lk; 
,) jpUkzk; nra;J itf;f $lhJ 
<) Ntiyf;F nry;;y mDkjpf;f $lhJ 
8. typg;G Neha; te;jth;fs; nra;af; $baJ? 
m) thfdq;fspy; ntFJ}uk; vq;F nrd;whYk; Jizf;F xU Ms; itj;J nfhs;tJ ey;yJ 
M) ntF J}uk; thfdk; Xl;lyhk; 
,) kUj;Jth; mwpTiug;gb kUe;J khj;jpiufis rhg;gpl Njitapy;iy. 
<) kJ mUe;jyhk;> rpfnul; Fbf;fyhk; 
9. typg;G Neha; cs;sth;fis rKjhak; vg;gb elj;j Ntz;Lk;? 
m) KO MjuTld; ,Uf;f Ntz;Lk;  
M) mth;fis xJf;f $lhJ 
,) typg;G Neuj;jpy; mth;fSf;F KjYjtp nra;a Ntz;Lk; 
<) ,it midj;Jk; 
10. typg;G Nehiag; gw;wp rKjhaj;jpd; fUj;J? 
m) Fzg;gLj;jNt Kbahj Neha; 
M) KOikahf Fzg;gLj;jf;$ba Neha; 
,) KOikahf fl;Lg;gLj;j $ba Neha; 
<) njupahJ 
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